<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">34323</article-id><article-id pub-id-type="doi">10.7554/eLife.34323</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Developmental Biology</subject></subj-group></article-categories><title-group><article-title>VEGF-C promotes the development of lymphatics in bone and bone loss</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-103813"><name><surname>Hominick</surname><given-names>Devon</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-103814"><name><surname>Silva</surname><given-names>Asitha</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-103815"><name><surname>Khurana</surname><given-names>Noor</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-103816"><name><surname>Liu</surname><given-names>Ying</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-103817"><name><surname>Dechow</surname><given-names>Paul C</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-103818"><name><surname>Feng</surname><given-names>Jian Q</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-103819"><name><surname>Pytowski</surname><given-names>Bronislaw</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-103820"><name><surname>Rutkowski</surname><given-names>Joseph M</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-10948"><name><surname>Alitalo</surname><given-names>Kari</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" corresp="yes" id="author-102943"><name><surname>Dellinger</surname><given-names>Michael T</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-3315-4239</contrib-id><email>michael.dellinger@utsouthwestern.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Hamon Center for Therapeutic Oncology Research</institution><institution>UT Southwestern Medical Center</institution><addr-line><named-content content-type="city">Dallas</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">Biomedical Sciences</institution><institution>Texas A&amp;M College of Dentistry</institution><addr-line><named-content content-type="city">Dallas</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Eli Lilly and Company</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution content-type="dept">Division of Lymphatic Biology, Department of Medical Physiology</institution><institution>Texas A&amp;M College of Medicine</institution><addr-line><named-content content-type="city">Texas</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution content-type="dept">Wihuri Research Institute and Translational Cancer Biology Program, Biomedicum Helsinki</institution><institution>University of Helsinki</institution><addr-line><named-content content-type="city">Helsinki</named-content></addr-line><country>Finland</country></aff><aff id="aff6"><label>6</label><institution content-type="dept">Hamon Center for Regenerative Science and Medicine</institution><institution>UT Southwestern Medical Center</institution><addr-line><named-content content-type="city">Dallas</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution content-type="dept">Division of Surgical Oncology, Department of Surgery</institution><institution>UT Southwestern Medical Center</institution><addr-line><named-content content-type="city">Dallas</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-31389"><name><surname>Gerhardt</surname><given-names>Holger</given-names></name><role>Reviewing Editor</role><aff id="aff8"><institution>Max Delbrück Centre for Molecular Medicine</institution><country>Germany</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>05</day><month>04</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>7</volume><elocation-id>e34323</elocation-id><history><date date-type="received" iso-8601-date="2017-12-13"><day>13</day><month>12</month><year>2017</year></date><date date-type="accepted" iso-8601-date="2018-03-22"><day>22</day><month>03</month><year>2018</year></date></history><permissions><copyright-statement>© 2018, Hominick et al</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Hominick et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-34323-v2.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.34323.001</object-id><p>Patients with Gorham-Stout disease (GSD) have lymphatic vessels in their bones and their bones gradually disappear. Here, we report that mice that overexpress VEGF-C in bone exhibit a phenotype that resembles GSD. To drive VEGF-C expression in bone, we generated <italic>Osx-tTA;TetO-Vegfc</italic> double-transgenic mice. In contrast to <italic>Osx-tTA</italic> mice, <italic>Osx-tTA;TetO-Vegfc</italic> mice developed lymphatics in their bones. We found that inhibition of VEGFR3, but not VEGFR2, prevented the formation of bone lymphatics in <italic>Osx-tTA;TetO-Vegfc</italic> mice. Radiological and histological analysis revealed that bones from <italic>Osx-tTA;TetO-Vegfc</italic> mice were more porous and had more osteoclasts than bones from <italic>Osx-tTA</italic> mice. Importantly, we found that bone loss in <italic>Osx-tTA;TetO-Vegfc</italic> mice could be attenuated by an osteoclast inhibitor. We also discovered that the mutant phenotype of <italic>Osx-tTA;TetO-Vegfc</italic> mice could be reversed by inhibiting the expression of VEGF-C. Taken together, our results indicate that expression of VEGF-C in bone is sufficient to induce the pathologic hallmarks of GSD in mice.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>lymphangiogenesis</kwd><kwd>lymphatic diseases</kwd><kwd>lymphatic anomalies</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>The Lymphatic Malformation Institute</institution></institution-wrap></funding-source><award-id>Research Grant</award-id><principal-award-recipient><name><surname>Dellinger</surname><given-names>Michael T</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution>The Department of Surgery at UT Southwestern Medical Center (MTD)</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Dellinger</surname><given-names>Michael T</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Mice that overexpress VEGF-C in bone display a phenotype that resembles Gorham-Stout disease.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Lymphatic vessels perform several essential functions in the body. Lymphatic vessels absorb intestinal lipids, transport immune cells, and return fluid and macromolecules to the blood vasculature (<xref ref-type="bibr" rid="bib60">Witte et al., 1997</xref>; <xref ref-type="bibr" rid="bib66">Zheng et al., 2014</xref>). Most soft tissues in the body have lymphatic vessels (<xref ref-type="bibr" rid="bib60">Witte et al., 1997</xref>). In contrast, hard tissues such as enamel, dentin, and bone do not have lymphatic vessels. Gorham-Stout disease (GSD) is a sporadic disease that is characterized by the presence of lymphatics in bone and bone loss (<xref ref-type="bibr" rid="bib15">Gorham and Stout, 1955</xref>; <xref ref-type="bibr" rid="bib10">Dellinger et al., 2014</xref>). J.B.S. Jackson is credited with publishing the first case of GSD, which appeared in the Boston Medical and Surgical Journal in 1838 (<xref ref-type="bibr" rid="bib22">Jackson, 1838</xref>). In his paper entitled ‘A Boneless Arm’, Jackson described a patient whose humerus had completely disappeared (<xref ref-type="bibr" rid="bib22">Jackson, 1838</xref>). Over 100 years later, Gorham and colleagues published a paper that described two additional cases of massive bone loss (<xref ref-type="bibr" rid="bib16">Gorham et al., 1954</xref>). They were able to analyze multiple affected bones from one patient and found that the bones were filled with irregular vessels (<xref ref-type="bibr" rid="bib16">Gorham et al., 1954</xref>). This interesting observation inspired Gorham and Stout to review additional cases of massive bone loss. Over several years, Gorham and Stout were able to acquire biopsy specimens from seven patients seen by other physicians (<xref ref-type="bibr" rid="bib15">Gorham and Stout, 1955</xref>). They observed abnormal vessels in each of the bone biopsy specimens they analyzed (<xref ref-type="bibr" rid="bib15">Gorham and Stout, 1955</xref>). This finding led Gorham and Stout to report that massive bone loss is associated with the growth of vessels in bone (<xref ref-type="bibr" rid="bib15">Gorham and Stout, 1955</xref>). It is now known that bones from GSD patients are filled with lymphatic vessels (<xref ref-type="bibr" rid="bib30">Lala et al., 2013</xref>; <xref ref-type="bibr" rid="bib46">Ozeki et al., 2016</xref>; <xref ref-type="bibr" rid="bib12">Edwards et al., 2008</xref>).</p><p>Since Gorham and Stout’s landmark publication, more than 300 cases of GSD have been described (<xref ref-type="bibr" rid="bib10">Dellinger et al., 2014</xref>). These case reports have further defined the clinical characteristics of the disease. GSD affects males and females equally and is most commonly diagnosed in children and young adults (<xref ref-type="bibr" rid="bib10">Dellinger et al., 2014</xref>). The course of this disease is often unpredictable. In some patients, the disease progresses slowly over a period of years, whereas in others, it progresses rapidly over a period of months (<xref ref-type="bibr" rid="bib10">Dellinger et al., 2014</xref>). In severe cases, the disease progresses until entire bones are lost and replaced by fibrous tissue. The disease is reported to arrest and stabilize after a variable period of activity. Importantly, affected bones do not regenerate after the disease has arrested (<xref ref-type="bibr" rid="bib10">Dellinger et al., 2014</xref>). Although GSD can affect any bone in the body, it most frequently affects the ribs and vertebrae (<xref ref-type="bibr" rid="bib10">Dellinger et al., 2014</xref>; <xref ref-type="bibr" rid="bib30">Lala et al., 2013</xref>). Unfortunately, thoracic involvement is associated with a poor prognosis because these patients tend to develop chylothorax, a complication that can cause respiratory distress, failure, and death (<xref ref-type="bibr" rid="bib30">Lala et al., 2013</xref>; <xref ref-type="bibr" rid="bib37">Ludwig et al., 2016</xref>). Despite advances in the understanding of the clinical features of the disease, the cause of GSD remains unknown and there are no standard treatments for this disease.</p><p>Vascular endothelial growth factor-C (VEGF-C) is the principle driver of lymphangiogenesis. Full-length VEGF-C undergoes proteolytic processing, which increases its affinity for VEGFR2 and VEGFR3 (<xref ref-type="bibr" rid="bib26">Joukov et al., 1996</xref>; <xref ref-type="bibr" rid="bib27">Joukov et al., 1997</xref>). Studies with genetically engineered mice have revealed that loss of VEGF-C impairs the development of the lymphatic vasculature. Mice that completely lack VEGF-C do not form lymphatics, whereas mice that lack a single copy of the VEGF-C gene develop fewer lymphatics than wildtype mice (<xref ref-type="bibr" rid="bib11">Dellinger et al., 2007</xref>; <xref ref-type="bibr" rid="bib28">Karkkainen et al., 2004</xref>). Conversely, tissue-specific overexpression of VEGF-C has been shown to induce lymphangiogenesis in the pancreas (<xref ref-type="bibr" rid="bib38">Mandriota et al., 2001</xref>), lungs (<xref ref-type="bibr" rid="bib61">Yao et al., 2014</xref>), and skin (<xref ref-type="bibr" rid="bib23">Jeltsch et al., 1997</xref>; <xref ref-type="bibr" rid="bib36">Lohela et al., 2008</xref>). In the present study, we characterize the effect of VEGF-C overexpression in bone on lymphatics and bone structure.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>VEGF-C induces the formation of bone lymphatics</title><p>Osterix (<bold>Osx</bold>) is a transcription factor expressed by chondrocytes, osteocytes, and osteoblasts (<xref ref-type="bibr" rid="bib67">Zhou et al., 2010</xref>). A transgenic mouse line was previously created in which the expression of a tetracycline transactivator (tTA) cassette was placed under the control of the Osx promoter (<xref ref-type="bibr" rid="bib50">Rodda and McMahon, 2006</xref>). This transgenic mouse line also has a <italic>TetO-Cre::GFP</italic> cassette located immediately downstream of the tTA cassette (<xref ref-type="bibr" rid="bib50">Rodda and McMahon, 2006</xref>). To identify cell types that display tTA activity in <italic>Osx-tTA-TetO-Cre::GFP</italic> mice, we characterized the expression pattern of the Cre::GFP fusion protein with an anti-green fluorescent protein (GFP) antibody. GFP was expressed by chondrocytes, osteocytes, and osteoblasts (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). GFP was not expressed by cells in the kidney, liver, lung, pancreas, skeletal muscle, or spleen (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). These data show that tTA activity in <italic>Osx-tTA-TetO-Cre::GFP</italic> mice (herein referred to as <italic>Osx-tTA</italic>) is restricted to bone.</p><p>To induce VEGF-C expression in bone, we bred <italic>Osx-tTA</italic> transgenic mice with <italic>TetO-Vegfc</italic> transgenic mice (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). No viable <italic>Osx-tTA;TetO-Vegfc</italic> offspring were obtained from these crosses. To determine whether <italic>Osx-tTA;TetO-Vegfc</italic> mice died during embryonic development, we analyzed mice on embryonic day (E)12.5, E14.5, and E16.5. <italic>Osx-tTA;TetO-Vegfc</italic> mice were grossly indistinguishable from control littermates on E12.5. However, <italic>Osx-tTA;TetO-Vegfc</italic> mice were severely edematous and displayed enlarged lymphatics on E14.5. All <italic>Osx-tTA;TetO-Vegfc</italic> mice were in the process of being resorbed on E16.5 (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). These data indicate that VEGF-C expression by bone cells during embryonic development has a lethal effect. To overcome this lethal effect, we bred <italic>Osx-tTA</italic> mice with <italic>TetO-Vegfc</italic> mice and placed mice on doxycycline water from E0.5 to E18.5. Mice were then placed on normal water to induce the expression of VEGF-C during postnatal development. To determine whether VEGF-C expression by bone cells induced the formation of bone lymphatics, we stained femurs from 21, 28, and 35-day-old <italic>Osx-tTA</italic> and <italic>Osx-tTA;TetO-Vegfc</italic> mice with an anti-podoplanin antibody. Lymphatic vessels were not present in femurs from 21, 28, or 35-day-old <italic>Osx-tTA</italic> mice. Similarly, lymphatic vessels were not present in femurs from 21-day-old <italic>Osx-tTA;TetO-Vegfc</italic> mice. In contrast, lymphatic vessels were present in femurs from 28-day-old <italic>Ox-tTA;TetO-Vegfc</italic> mice. However, lymphatic vessels were restricted to cortical bone (the dense outer shell of bone). In 35-day-old <italic>Osx-tTA;TetO-Vegfc</italic> mice, lymphatic vessels were located in cortical bone, trabecular bone, and the marrow cavity (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Tibias and ribs from 35-day-old <italic>Osx-tTA;TetO-Vegfc</italic> mice also had lymphatics (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>). These vessels expressed Lyve-1, another marker of lymphatic endothelium (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>). Although 35-day-old <italic>Osx-tTA;TetO-Vegfc</italic> mice had hyperplastic lymphatics in bones, lymphatics in soft tissues (kidney, liver, lungs, and pancreas) appeared normal and the circulating level of VEGF-C was not elevated (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>). These data indicate that expression of VEGF-C in bone induces the formation of bone lymphatics, but not the growth of lymphatics in distant tissues.</p><fig-group><fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.34323.002</object-id><label>Figure 1.</label><caption><title><italic>Osx-tTA;TetO-Vegfc</italic> mice develop lymphatics in their bones.</title><p>(<bold>A</bold>) Schematic of the Tet-Off system used to express VEGF-C in bone. Doxycycline inhibits the expression of VEGF-C. (<bold>B</bold>) Schematic showing when mice received normal water and doxycycline water. <italic>Osx-tTA</italic> and <italic>Osx-tTA;TetO-Vegfc</italic> mice received doxycycline water from E0.5 to E18.5 and then normal water from E18.5 to P35. (<bold>C–H</bold>) Representative images of cortical bone in <italic>Osx-tTA</italic> and <italic>Osx-tTA;TetO-Vegfc</italic> femurs. Sections were stained with an anti-podoplanin antibody. Arrowheads point to podoplanin-positive osteocytes. Arrows point to podoplanin-positive lymphatics. (<bold>I</bold>) Graph showing lymphatic vessel index values for cortical bone in P21 (0 ± 0.0; n = 3), P28 (0 ± 0.0; n = 5), and P35 (0 ± 0.0; n = 6) <italic>Osx-tTA</italic> mice and in P21 (0 ± 0.0; n = 4), P28 (67 ± 22.06; n = 4), and P35 (130.3 ± 44.35; n = 4) <italic>Osx-tTA;TetO-Vegfc</italic> mice. (<bold>J–O</bold>) Representative images of trabecular bone in <italic>Osx-tTA</italic> and <italic>Osx-tTA;TetO-Vegfc</italic> femurs. Sections were stained with an anti-podoplanin antibody. Arrowheads point to podoplanin-positive osteocytes. Arrow points to podoplanin-positive lymphatics. (<bold>P</bold>) Graph showing lymphatic vessel index values for trabecular bone in P21 (0 ± 0.0; n = 3), P28 (0 ± 0.0; n = 5), and P35 (0 ± 0.0; n = 6) <italic>Osx-tTA</italic> mice and P21 (0 ± 0.0; n = 4), P28 (0.167 ± 0.4082; n = 6), and P35 (189.5 ± 47.7; n = 4) <italic>Osx-tTA;TetO-Vegfc</italic> mice. (***p&lt;0.001, ****p&lt;0.0001, unpaired student’s T-test). ND = Not Detected.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-34323-fig1-v2"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.34323.003</object-id><label>Figure 1—figure supplement 1.</label><caption><title>Expression pattern of GFP in <italic>Osx-tTA-TetO-tTA-Cre::GFP</italic> mice.</title><p>(<bold>A</bold>) Schematic of the <italic>Osx-tTA-TetO-tTA-Cre::GFP</italic> cassette. When doxycycline is absent, tetracycline transactivator (tTA) induces the expression of a Cre::GFP fusion protein. (<bold>B</bold>) Representative images of tissues stained with an anti-GFP antibody. Tissues were collected from P35 <italic>Osx-tTA-TetO-tTA-Cre::GFP</italic> mice that were maintained on normal water. Chondrocytes, osteocytes (arrowheads), and osteoblasts (arrows) expressed GFP. Cells in the liver, lung, muscle, pancreas, spleen, and kidney did not express GFP.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-34323-fig1-figsupp1-v2"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.34323.004</object-id><label>Figure 1—figure supplement 2.</label><caption><title>Expression of VEGF-C during embryonic development causes embryonic lethality.</title><p>(<bold>A</bold>) Schematic showing when mice received normal water. (<bold>B–C</bold>) Representative images of E12.5, E14.5 and E16.5 control embryos. (<bold>E–G</bold>) Representative images of E12.5, E14.5 and E16.5 <italic>Osx-tTA;TetO-Vegfc</italic> embryos. (<bold>H,I</bold>) Transverse sections of E14.5 embryos stained with hematoxylin and eosin. The jugular lymph sac (asterisk) in the control embryo appears normal. In contrast, the jugular lymph sac (asterisk) in the <italic>Osx-tTA;TetO-Vegfc</italic> embryo is enlarged.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-34323-fig1-figsupp2-v2"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.34323.005</object-id><label>Figure 1—figure supplement 3.</label><caption><title>Bone lymphatics express Lyve-1.</title><p>(<bold>A</bold>) No Lyve-1-positive cells are in tibias from P35 <italic>Osx-tTA</italic> mice. (<bold>B</bold>) Numerous Lyve-1-positive lymphatics are in tibias from P35 <italic>Osx-tTA;TetO-Vegfc</italic> mice. (<bold>C</bold>) No Lyve-1-positive cells are in ribs from P35 <italic>Osx-tTA</italic> mice. (<bold>D</bold>) Numerous Lyve-1-positive lymphatics are in ribs from P35 <italic>Osx-tTA;TetO-Vegfc</italic> mice.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-34323-fig1-figsupp3-v2"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.34323.006</object-id><label>Figure 1—figure supplement 4.</label><caption><title>Lymphatics in soft tissues in <italic>Osx-tTA;TetO-Vegfc</italic> mice appear normal.</title><p>(<bold>A</bold>) Representative pictures of tissues collected from P35 <italic>Osx-tTA</italic> and <italic>Osx-tTA;TetO-Vegfc</italic> mice. Lymphatics in the lung, liver, kidney, and pancreas appeared normal in <italic>Osx-tTA;TetO-Vegfc</italic> mice. (<bold>B</bold>) Graph showing the circulating level of VEGF-C in P35 <italic>Osx-tTA</italic> (2.04 ± 1.42, n = 8) and <italic>Osx-tTA;TetO-Vegfc</italic> (2.387 ± 0.94, n = 7) mice.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-34323-fig1-figsupp4-v2"/></fig></fig-group></sec><sec id="s2-2"><title>VEGFR3 signaling is required for the formation of bone lymphatics</title><p>VEGF-C activates VEGFR2 and VEGFR3 (<xref ref-type="bibr" rid="bib26">Joukov et al., 1996</xref>). However, VEGF-C is thought to primarily induce lymphangiogenesis by activating VEGFR3 (<xref ref-type="bibr" rid="bib57">Veikkola et al., 2001</xref>). To determine whether VEGF-C activation of VEGFR2 or VEGFR3 was required for the formation of bone lymphatics, we treated 21-day-old <italic>Osx-tTA;TetO-Vegfc</italic> mice with vehicle, DC101 (VEGFR2 function-blocking antibody), or mF4-31C1 (VEGFR3 function-blocking antibody) for 2 weeks. The density of bone lymphatics was modestly reduced in DC101-treated mice. In contrast, bone lymphatics failed to form in mF4-31C1-treated mice (<xref ref-type="fig" rid="fig2">Figure 2</xref>). These data show that VEGFR3 signaling is required for the development of bone lymphatics in <italic>Osx-tTA;TetO-Vegfc</italic> mice.</p><fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.34323.007</object-id><label>Figure 2.</label><caption><title>VEGFR3 signaling promotes the formation of bone lymphatics.</title><p>(<bold>A</bold>) Schematic showing when mice received normal water and doxycycline water. <italic>Osx-tTA;TetO-Vegfc</italic> mice were treated (3x/week) with vehicle, DC101 (VEGFR2 function-blocking antibody), or mF4-31C1 (VEGFR3 function-blocking antibody) from P21 to P35. (<bold>B</bold>) Graph showing lymphatic index values for vehicle-treated (182.6 ± 61.56; n = 7), DC101-treated (99 ± 41.68; n = 7), and mF4-31C1-treated mice (0 ± 0.0; n = 5). (**p&lt;0.01, ****p&lt;0.0001, ANOVA followed by Dunnett’s multiple comparisons test. Values were tested against values for vehicle-treated mice). (<bold>C–E</bold>) Representative images of femurs stained with an anti-podoplanin antibody. The femurs are from P35 mice. Arrows in panel E point to podoplanin-positive osteocytes. (<bold>F</bold>) Representative image of a femur from an <italic>Osx-tTA;TetO-Vegfd</italic> mouse that was stained with an anti-podoplanin antibody. Arrows point to podoplanin-positive lymphatics in the bone marrow. (<bold>G</bold>) Graph showing lymphatic vessel index values for trabecular bone in P35 <italic>Osx-tTA</italic> mice (0 ± 0; n = 6), <italic>Osx-tTA;TetO-Vegfc</italic> mice (189.5 ± 47.7; n = 4), and <italic>Osx-tTA;TetO-Vegfd</italic> mice (293 ± 37.24; n = 3). (****p&lt;0.0001, ANOVA followed by Dunnett’s multiple comparisons test. Values were tested against values for <italic>Osx-tTA</italic> mice). ND = Not Detected.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-34323-fig2-v2"/></fig><p>In contrast to murine VEGF-C, murine VEGF-D only activates VEGFR3 (<xref ref-type="bibr" rid="bib2">Baldwin et al., 2001</xref>). A transgenic mouse strain was recently created in which the expression of murine VEGF-D is controlled by doxycycline (<xref ref-type="bibr" rid="bib31">Lammoglia et al., 2016</xref>). To determine whether murine VEGF-D could induce the formation of bone lymphatics, we generated <italic>Osx-tTA;TetO-Vegfd</italic> mice. <italic>Osx-tTA;TetO-Vegfd</italic> mice received doxycycline water from E0.5 to E18.5 and then normal water from E18.5 to postnatal day (P) 35. Importantly, femurs from <italic>Osx-tTA;TetO-Vegfd</italic> mice were filled with lymphatic vessels (<xref ref-type="fig" rid="fig2">Figure 2</xref>). These data show that activation of VEGFR3 is sufficient for the formation of bone lymphatics.</p></sec><sec id="s2-3"><title>Bone loss in <italic>Osx-tTA;TetO-Vegfc</italic> mice is mediated by osteoclasts</title><p>To characterize the effect of VEGF-C expression by bone cells on bone structure, we X-rayed femurs from 21, 28, and 35-day-old <italic>Osx-tTA</italic> and <italic>Osx-tTA;TetO-Vegfc</italic> mice. Femurs from 21-day-old <italic>Osx-tTA;TetO-Vegfc</italic> mice appeared normal and were indistinguishable from femurs from <italic>Osx-tTA</italic> mice (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). In contrast, femurs from 28- and 35-day-old <italic>Osx-tTA;TetO-Vegfc</italic> mice had a moth-eaten appearance (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). The development of this phenotype coincided with the formation of lymphatics in cortical bone. To further characterize the structure of cortical bone, we took μCT images of femurs and ribs from 35-day-old <italic>Osx-tTA</italic> and <italic>Osx-tTA;TetO-Vegfc</italic> mice. This revealed that bones from <italic>Osx-tTA;TetO-Vegfc</italic> mice were significantly more porous than bones from <italic>Osx-tTA</italic> mice (<xref ref-type="fig" rid="fig3">Figure 3</xref>). To determine whether the structural defects in <italic>Osx-tTA;TetO-Vegfc</italic> bones affected bone strength, we performed a three-point bending assay. The three-point bending assay revealed that femurs from <italic>Osx-tTA;TetO-Vegfc</italic> mice were significantly weaker than femurs from <italic>Osx-tTA</italic> mice (<xref ref-type="fig" rid="fig3">Figure 3</xref>).</p><fig-group><fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.34323.008</object-id><label>Figure 3.</label><caption><title><italic>Osx-tTA;TetO-Vegfc</italic> mice have more porous bones and osteoclasts than <italic>Osx-tTA</italic> mice.</title><p>(<bold>A,B</bold>) Representative μCT images of femurs from <italic>Osx-tTA</italic> and <italic>Osx-tTA;TetO-Vegfc mice</italic>. (<bold>C</bold>) Graph showing cortical bone porosity for femurs from <italic>Osx-TA</italic> (0.062 ± 0.0292, n = 5) and <italic>Osx-tTA;TetO-Vegfc</italic> (0.209 ± 0.0204, n = 6) mice. (<bold>D,E</bold>) Representative μCT images of ribs from <italic>Osx-tTA</italic> and <italic>Osx-tTA;TetO-Vegfc mice</italic>. (<bold>F</bold>) Graph showing cortical bone porosity for ribs from <italic>Osx-TA</italic> (0.024 ± 0.00293, n = 4) and <italic>Osx-tTA;TetO-Vegfc</italic> (0.165 ± 0.0265, n = 4) mice. (<bold>G</bold>) Graph showing results from the three-point bending assay. Less force was required to break bones from <italic>Osx-TA;TetO-Vegfc</italic> mice (5.96 ± 1.404, n = 11) than <italic>Osx-tTA</italic> mice (9.231 ± 1.355, n = 9) mice. (<bold>H,I</bold>) Representative images of TRAP-stained femurs from <italic>Osx-tTA</italic> and <italic>Osx-tTA;TetO-Vegfc</italic> mice. (<bold>J</bold>) Graph showing the number of osteoclasts per mm of bone for <italic>Osx-tTA</italic> (1.18 ± 0.6818; n = 4) and <italic>Osx-tTA;TetO-Vegfc</italic> (6.84 ± 1.413; n = 4) mice. (<bold>K</bold>) Graph showing CTX-1 values for <italic>Osx-tTA</italic> (1.7 ± 2.045; n = 8) and <italic>Osx-tTA;TetO-Vegfc</italic> (53.3 ± 31.8; n = 7) mice. (***p&lt;0.001, ****p&lt;0.0001, unpaired student’s T-test).</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-34323-fig3-v2"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.34323.009</object-id><label>Figure 3—figure supplement 1.</label><caption><title>Bones from <italic>Osx-tTA;TetO-Vegfc</italic> mice have a moth-eaten appearance.</title><p>Representative images of x-rayed femurs from <italic>Osx-tTA</italic> and <italic>Osx-tTA;TetO-Vegfc</italic> mice. (<bold>A–C</bold>) Femurs from P21, P28, and P35 <italic>Osx-tTA</italic> mice appear normal. (<bold>D–E</bold>) Femurs from P21 <italic>Osx-tTA;TetO-Vegfc</italic> mice appear normal, whereas femurs from P28 and P35 <italic>Osx-tTA;TetO-Vegfc</italic> mice have a moth-eaten appearance (arrows).</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-34323-fig3-figsupp1-v2"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.34323.010</object-id><label>Figure 3—figure supplement 2.</label><caption><title>LECs do not degrade a calcium-phosphate matrix.</title><p>(<bold>A</bold>) Schematic for experiment with the Osteo-Assay plate. (<bold>B,C</bold>) Representative images of wells containing lymphatic endothelial cells or RAW64.7 cells (osteoclasts). (<bold>D</bold>) Graph showing the percent area resorbed by lymphatic endothelial cells (0 ± 0.0; n = 3) and RAW264.7 cells (50.83 ± 4.131, n = 3). ****p&lt;0.0001.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-34323-fig3-figsupp2-v2"/></fig></fig-group><p>Next, we set out to delineate the cause of bone loss in <italic>Osx-tTA;TetO-Vegfc</italic> mice. To determine whether lymphatic endothelial cells (LECs) could directly degrade bone, we cultured RAW264.7 cells (osteoclast precursor cell line) and primary human LECs in separate wells of an osteo-assay surface plate. The osteo-assay surface plate has a calcium-phosphate coating that mimics bone. After culturing cells for 72 hr, we observed numerous resorption pits in wells containing differentiated RAW264.7 cells (osteoclasts), but not in wells containing LECs (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>). This finding suggests that LECs do not directly degrade bone.</p><p>Osteoclasts are multi-nucleated cells that degrade bone and display tartrate-resistant acid phosphatase (TRAP) activity. To determine whether there was a difference in the number of osteoclasts between <italic>Osx-tTA</italic> and <italic>Osx-tTA;TetO-Vegfc</italic> mice, we stained bones from 35-day-old mice for TRAP activity. This staining revealed that there were significantly more osteoclasts on the surface of cortical bone in <italic>Osx-tTA;TetO-Vegfc</italic> mice than in <italic>Osx-tTA</italic> mice (<xref ref-type="fig" rid="fig3">Figure 3</xref>). To extend this finding, we also measured the circulating levels of C-terminal telopeptide of type I collagen (CTX-1) in <italic>Osx-tTA</italic> and <italic>Osx-tTA;TetO-Vegfc</italic> mice. CTX-1 is a small peptide generated by osteoclast-mediated cleavage of collagen I (<xref ref-type="bibr" rid="bib13">Garnero et al., 2003</xref>). Importantly, CTX-1 was significantly higher in <italic>Osx-tTA;TetO-Vegfc</italic> mice than <italic>Osx-tTA</italic> mice (<xref ref-type="fig" rid="fig3">Figure 3</xref>). Together, these data show that the number and activity of osteoclasts are increased in <italic>Osx-tTA;TetO-Vegfc</italic> mice.</p><p>Zoledronic acid (also known as Zometa) is a drug that accumulates in bone and prevents bone resorption by inhibiting farnesyl pyrophosphate synthase activity in osteoclasts (<xref ref-type="bibr" rid="bib8">Clézardin, 2013</xref>). To determine whether osteoclasts promote bone resorption in <italic>Osx-tTA;TetO-Vegfc</italic> mice, we treated 21-day-old mice with either vehicle or zoledronic acid for 2 weeks. The density of bone lymphatics was not significantly different between zoledronic acid-treated and vehicle-treated <italic>Osx-tTA;TetO-Vegfc</italic> mice (<xref ref-type="fig" rid="fig4">Figure 4</xref>). However, the number of osteoclasts and porosity of femurs were significantly lower in zoledronic acid-treated mice than vehicle-treated mice (<xref ref-type="fig" rid="fig4">Figure 4</xref>). These data indicate that bone loss in <italic>Osx-tTA;TetO-Vegfc</italic> mice is driven by osteoclasts.</p><fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.34323.011</object-id><label>Figure 4.</label><caption><title>Zoledronic acid attenuates bone loss in <italic>Osx-tTA;TetO-Vegfc</italic> mice.</title><p>(<bold>A</bold>) Schematic showing when mice received normal water and doxycycline water. <italic>Osx-tTA;TetO-Vegfc</italic> mice were treated (q.a.d.) with vehicle or zoledronic acid from P21 to P35. (<bold>B,C</bold>) Representative images of femurs stained with an anti-podoplanin antibody. (<bold>D</bold>) Graph showing lymphatic vessel index values for vehicle-treated (171.5 ± 18.18, n = 3) and zoledronic acid-treated (165.2 ± 18.04, n = 5) mice. (<bold>E,F</bold>) Representative images of TRAP stained femurs from vehicle-treated and zoledronic acid-treated mice. (<bold>G</bold>) Graph showing the number of osteoclasts per mm of bone for vehicle-treated (7.0 ± 3.15, n = 3) and zoledronic acid-treated (1.9 ± 1.9, n = 5) mice. (<bold>H,I</bold>) Representative images of H and E stained femurs from vehicle-treated and zoledronic acid-treated mice. (<bold>J</bold>) Graph showing cortical bone porosity of femurs for vehicle-treated (0.092 ± 0.0245, n = 3) and zoledronic acid-treated (0.030 ± 0.0103, n = 5) mice. (*p&lt;0.05, **p&lt;0.01, unpaired student’s T-test).</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-34323-fig4-v2"/></fig><p>To determine whether inhibition of lymphangiogenesis could prevent osteoclastogenesis and bone loss in <italic>Osx-tTA;TetO-Vegfc</italic> mice, we analyzed femurs from vehicle and mF4-31C1-treated mice. We focused our analysis on mF4-31C1-treated mice because these mice do not develop bone lymphatics (<xref ref-type="fig" rid="fig2">Figure 2</xref>). We found that femurs from mF4-31C1-treated mice had significantly fewer osteoclasts than femurs from vehicle-treated mice (<xref ref-type="fig" rid="fig5">Figure 5</xref>). Additionally, we found that femurs from mF4-31C1-treated mice were significantly less porous than femurs from vehicle-treated mice (<xref ref-type="fig" rid="fig5">Figure 5</xref>). These data show that inhibition of lymphangiogenesis can prevent osteoclastogenesis and bone loss in <italic>Osx-tTA;TetO-Vegfc</italic> mice.</p><fig id="fig5" position="float"><object-id pub-id-type="doi">10.7554/eLife.34323.012</object-id><label>Figure 5.</label><caption><title>mF4-31C1 inhibits osteoclast formation and bone loss in <italic>Osx-tTA;TetO-Vegfc</italic> mice.</title><p>(<bold>A</bold>) Schematic showing when mice received normal water and doxycycline water. <italic>Osx-tTA;TetO-Vegfc</italic> mice were treated (3x/week) with vehicle or mF4-31C1 (VEGFR3 function-blocking antibody) from P21 to P35. (<bold>B,C</bold>) Representative images of TRAP stained femurs from vehicle-treated and mF4-31C1-treated mice. (<bold>D</bold>) Graph showing the number of osteoclasts per mm of bone for vehicle-treated (7.37 ± 2.088, n = 5) and mF4-31C1-treated (2.552 ± 0.6893, n = 5) mice. (<bold>E,F</bold>) Representative images of H and E stained femurs from vehicle-treated and mF4-31C1-treated mice. (<bold>G</bold>) Graph showing cortical bone porosity of femurs for vehicle-treated (0.07244 ± 0.02468, n = 5) and mF4-31C1-treated (0.006375 ± 0.007087, n = 4) mice. (**p&lt;0.01, unpaired student’s T-test).</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-34323-fig5-v2"/></fig></sec><sec id="s2-4"><title>Inhibition of VEGF-C expression reverses the mutant phenotype of <italic>Osx-tTA;TetO-Vegfc</italic> mice</title><p>Next, we set out to determine whether the mutant phenotype of <italic>Osx-tTA;TetO-Vegfc</italic> mice was reversible. We first characterized the reversibility of VEGF-C expression in <italic>Osx-tTA;TetO-Vegfc</italic> mice. We collected RNA from tibias from <italic>Osx-tTA</italic> mice, <italic>Osx-tTA;TetO-Vegfc</italic> mice that received normal water from E18.5 to P35, and <italic>Osx-tTA;TetO-Vegfc</italic> mice that received normal water from E18.5 to P35 and then doxycycline water for either 3 or 7 days (<xref ref-type="fig" rid="fig6">Figure 6</xref>). The expression of VEGF-C mRNA was then evaluated by qPCR. VEGF-C mRNA levels were approximately 350-fold higher in <italic>Osx-tTA;TetO-Vegfc</italic> mice than <italic>Osx-tTA</italic> mice. Importantly, VEGF-C mRNA levels in <italic>Osx-tTA;TetO-Vegfc</italic> mice returned to normal within 3 days of being placed back on doxycycline water (<xref ref-type="fig" rid="fig6">Figure 6</xref>). These data indicate that doxycycline rapidly inhibits the expression of VEGF-C in <italic>Osx-tTA;TetO-Vegfc</italic> mice.</p><fig id="fig6" position="float"><object-id pub-id-type="doi">10.7554/eLife.34323.013</object-id><label>Figure 6.</label><caption><title>Bone lymphatics in <italic>Osx-tTA;TetO-Vegfc</italic> mice disappear following the withdrawal of VEGF-C.</title><p>(<bold>A</bold>) Schematic showing when mice received normal water and doxycycline water. One cohort of <italic>Osx-tTA;TetO-Vegfc</italic> mice received normal water from E18.5 to P35 (On 35d). A second cohort of <italic>Osx-tTA;TetO-Vegfc</italic> mice received normal water from E18.5 to P35 and then doxycycline water from P35 to P38 (On 35d/Off 3d). A third cohort of <italic>Osx-tTA;TetO-Vegfc</italic> mice received normal water from E18.5 to P35 and then doxycycline water from P35 to P42 (On 35d/Off 7d). (<bold>B</bold>) Graph showing the relative VEGF-C mRNA levels in tibias from mice. (<bold>C</bold>) Schematic showing when mice received normal water and doxycycline water. <italic>Osx-tTA;TetO-Vegfc</italic> mice received normal water from E18.5 to P35 (On 35d) or normal water from E18.5 to P35 and then doxycycline water for 3 (On 35d/Off 3d), 7 (On 35d/Off 7d), 28 (On 35d/Off 28d), or 56 days (On 35d/Off 56d). (<bold>D–I</bold>) Representative images of ribs stained with an anti-podoplanin antibody. The dashed lines separate the bone from the periosseous muscle. (<bold>J</bold>) Graph showing lymphatic vessel index values for ribs in <italic>Osx-tTA</italic> mice (0 ± 0.0; n = 5), <italic>Osx-tTA;TetO-Vegfc</italic> mice that received normal water for 35 days (152.5 ± 29.56; n = 5), and <italic>Osx-tTA;TetO-Vegfc</italic> mice that received normal water for 35 days and then doxycycline water for 3 (62.25 ± 51.7; n = 4), 7 (24.08 ± 21.26; n = 4), 28 (0 ± 0.0; n = 5) or 56 (0 ± 0.0; n = 3) days. (<bold>K</bold>) Graph showing lymphatic vessel index values for periosseous muscle in <italic>Osx-tTA</italic> mice (3.61 ± 1.974; n = 5), <italic>Osx-tTA;TetO-Vegfc</italic> mice that received normal water for 35 days (92.45 ± 34.63; n = 5), and <italic>Osx-tTA;TetO-Vegfc</italic> mice that received normal water for 35 days and then doxycycline water for 3 (99.29 ± 23.37; n = 4), 7 (74.84 ± 18.98; n = 4), 28 (92.67 ± 24.2; n = 5) or 56 (72.17 ± 14.05; n = 3) days. (**p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001, ANOVA followed by Dunnett’s multiple comparisons test. Values were tested against values for <italic>Osx-tTA</italic> mice). ND = Not Detected.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-34323-fig6-v2"/></fig><p>To assess the reversibility of the lymphatic phenotype of <italic>Osx-tTA;TetO-Vegfc</italic> mice, we analyzed ribs from <italic>Osx-tTA</italic> mice, <italic>Osx-tTA;TetO-Vegfc</italic> mice that received normal water from E18.5 to P35, and <italic>Osx-tTA;TetO-Vegfc</italic> mice that received normal water from E18.5 to P35 and then doxycycline water for either 3, 7, 28, or 56 days (<xref ref-type="fig" rid="fig6">Figure 6</xref>). <italic>Osx-tTA</italic> mice did not have lymphatic vessels in their ribs and possessed a sparse network of lymphatics in their periosseous muscle (<xref ref-type="fig" rid="fig6">Figure 6</xref>). In contrast, <italic>Osx-tTA;TetO-Vegfc</italic> mice that received normal water from E18.5 to P35 had numerous lymphatic vessels in their ribs and an expanded network of lymphatics in their periosseous muscle (<xref ref-type="fig" rid="fig6">Figure 6</xref>). To our surprise, the abnormal lymphatic vessels in the ribs, but not in the periosseous muscle, gradually disappeared in <italic>Osx-tTA;TetO-Vegfc</italic> mice that received doxycycline (<xref ref-type="fig" rid="fig6">Figure 6</xref>). These data show that irregular lymphatic vessels in bone, but not in periosseous muscle, depend on continued VEGF-C signaling for their existence.</p><p>We next set out to characterize the reversibility of the bone phenotype of <italic>Osx-tTA;TetO-Vegfc</italic> mice. We X-rayed ribs from <italic>Osx-tTA</italic> mice, <italic>Osx-tTA;TetO-Vegfc</italic> mice that received normal water from E18.5 to P35, and <italic>Osx-tTA;TetO-Vegfc</italic> mice that received normal water from E18.5 to P35 and then doxycycline water for 28 days. Similar to what we observed for femurs (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>) ribs in <italic>Osx-tTA;TetO-Vegfc</italic> mice had a moth-eaten appearance (<xref ref-type="fig" rid="fig7">Figure 7</xref>). Amazingly, inhibition of VEGF-C expression caused ribs in <italic>Osx-tTA;TetO-Vegfc</italic> mice to switch from a moth-eaten appearance to a normal appearance (<xref ref-type="fig" rid="fig7">Figure 7</xref>). To further explore the effect of VEGF-C inhibition on bone structure in <italic>Osx-tTA;TetO-Vegfc</italic> mice, we evaluated cortical bone porosity in femur sections. Doxycycline caused cortical bone porosity in <italic>Osx-tTA;TetO-Vegfc</italic> mice to revert back to normal. We also found that the number of osteoclasts and the circulating levels of CTX-1 in <italic>Osx-tTA;TetO-Vegfc</italic> mice returned to normal after exposure to doxycycline (<xref ref-type="fig" rid="fig7">Figure 7</xref>). Together, these data show that the bone phenotype of <italic>Osx-tTA;TetO-Vegfc</italic> mice is reversible.</p><fig id="fig7" position="float"><object-id pub-id-type="doi">10.7554/eLife.34323.014</object-id><label>Figure 7.</label><caption><title>The bone phenotype of <italic>Osx-tTA;TetO-Vegfc</italic> mice is reversible.</title><p>(<bold>A–C</bold>) Representative x-ray images of femurs from <italic>Osx-tTA</italic> mice, <italic>Osx-tTA;TetO-Vegfc</italic> mice that received normal water from E18.5 to P35 (On 35d), and <italic>Osx-tTA;TetO-Vegfc</italic> mice that received normal water from E18.5 to P35 and then doxycycline water from P35 to P63 (On 35d/Off 28d). <italic>Osx-tTA;TetO-Vegfc</italic> femurs switched from a moth-eaten appearance to a normal appearance following exposure to doxycycline. (<bold>D</bold>) Graph showing cortical bone porosity values for femurs from <italic>Osx-tTA</italic> mice (0.011 ± 0.0103; n = 4), <italic>Osx-tTA;TetO-Vegfc</italic> mice that received normal water from E18.5 to P35 (0.149 ± 0.0615; n = 7), and <italic>Osx-tTA;TetO-Vegfc</italic> mice that received normal water from E18.5 to P35 and then doxycycline water from P35 to P63 (0.014 ± 0.0152; n = 5). (<bold>E–G</bold>) Representative images of H and E stained femurs. The femur from the <italic>Osx-tTA;TetO-Vegfc</italic> mouse that received normal water from E18.5 to P35 is filled with pores. (<bold>H</bold>) Graph showing the number of osteoclasts per mm of bone for <italic>Osx-tTA</italic> mice (1.18. ±0.6818; n = 4), <italic>Osx-tTA;TetO-Vegfc</italic> mice that received normal water from E18.5 to P35 (6.84 ± 1.41; n = 4), and <italic>Osx-tTA;TetO-Vegfc</italic> mice that received normal water from E18.5 to P35 and then doxycycline water from P35 to P63 (1.45 ± 1.88; n = 4). (<bold>I</bold>) Graph showing CTX-1 values for <italic>Osx-tTA</italic> mice (1.7 ± 2.045; n = 8), <italic>Osx-tTA;TetO-Vegfc</italic> mice that received normal water from E18.5 to P35 (53.3 ± 31.8; n = 7), and <italic>Osx-tTA;TetO-Vegfc</italic> mice that received normal water from E18.5 to P35 and then doxycycline water from P35 to P63 (1.9 ± 1.19; n = 4). (***p&lt;0.001, ANOVA followed by Dunnett’s multiple comparisons test. Values were tested against values for <italic>Osx-tTA</italic> mice.).</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-34323-fig7-v2"/></fig></sec><sec id="s2-5"><title><italic>Osx-tTA;TetO-Vegfc</italic> mice develop chylothorax</title><p>Chylothorax is frequently observed in GSD patients with thoracic involvement and is the leading cause of mortality of GSD patients (<xref ref-type="bibr" rid="bib37">Ludwig et al., 2016</xref>). During the course of our experiments we discovered that <italic>Osx-tTA;TetO-Vegfc</italic> mice die prematurely (<xref ref-type="fig" rid="fig8">Figure 8</xref>). When we examined moribund <italic>Osx-tTA;TetO-Vegfc</italic> mice, we found that their chest cavity was filled with fluid. The color of this fluid ranged from milky white to light pink. The triglyceride content of the fluid was greater than 110 mg/dl, which indicated that the effusion fluid was chyle (<xref ref-type="fig" rid="fig8">Figure 8</xref>). Chyle is lymph rich in fat that flows through the thoracic duct. To identify the route by which chyle escaped the thoracic duct in <italic>Osx-tTA;TetO-Vegfc</italic> mice, we injected the mesenteric lymph node of 35-day-old mice with Evans blue dye (EBD). EBD was confined to the thoracic duct in <italic>Osx-tTA</italic> mice. In contrast, EBD spilled from the thoracic duct into lymphatics in the periosseous muscle in <italic>Osx-tTA;TetO-Vegfc</italic> mice. EBD appeared to leak from the irregular lymphatics along the chest wall. These findings indicate that the lymphatics that form in the periosseous muscle do not function properly.</p><fig id="fig8" position="float"><object-id pub-id-type="doi">10.7554/eLife.34323.015</object-id><label>Figure 8.</label><caption><title><italic>Osx-tTA;TetO-Vegfc</italic> mice develop chylothorax.</title><p>(<bold>A</bold>) Survival curve for <italic>Osx-tTA</italic> and <italic>Osx-tTA;TetO-Vegfc</italic> mice (p&lt;0.0001 Log-rank (Mantel-Cox) test). (<bold>B</bold>) Graph showing triglyceride levels in effusion fluid collected from <italic>Osx-tTA;TetO-Vegfc</italic> mice (n = 4). The dashed line marks 110 mg/dl. (<bold>C</bold>) Overview of the Evans blue dye (EBD) lymphangiography method. EBD injected into the mesenteric lymph node is transported to the thoracic duct. (<bold>D</bold>) EBD is confined to the thoracic duct in <italic>Osx-tTA</italic> mice (n = 4). (<bold>E</bold>) In <italic>Osx-tTA;TetO-Vegfc</italic> mice, EBD spills from the thoracic duct into periosseous lymphatics in muscle (n = 4).</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-34323-fig8-v2"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Patients with GSD have lymphatics in their bones and their bones gradually disappear. In this study, we show that overexpression of VEGF-C by bone cells induces the formation of bone lymphatics and bone loss. Taken together, our findings demonstrate that expression of VEGF-C in bone is sufficient to induce the pathologic hallmarks of GSD in mice.</p><p>VEGF-C has been shown to promote lymphangiogenesis in several different pathological settings. However, investigators have only recently started to examine VEGF-C levels in patients with GSD. The circulating level of VEGF-C was found to be slightly elevated in 1 GSD patient (<xref ref-type="bibr" rid="bib5">Brodszki et al., 2011</xref>), but not in two other GSD patients (<xref ref-type="bibr" rid="bib5">Brodszki et al., 2011</xref>; <xref ref-type="bibr" rid="bib4">Baud et al., 2015</xref>). We found that the local level, but not the circulating level, of VEGF-C was elevated in <italic>Osx-tTA;TetO-Vegfc</italic> mice. In the future, patient samples could be used to determine whether VEGF-C is locally elevated in affected tissues in GSD patients.</p><p>VEGF-C is a growth factor that promotes lymphangiogenesis in embryos and in adult tissues. VEGF-C activates VEGFR2 and VEGFR3 (<xref ref-type="bibr" rid="bib26">Joukov et al., 1996</xref>). However, VEGF-C has a greater affinity for VEGFR3 than VEGFR2 (<xref ref-type="bibr" rid="bib27">Joukov et al., 1997</xref>). We found that mF4-31C1 (VEGFR3 inhibitor) was more effective at inhibiting lymphangiogenesis in <italic>Osx-tTA;TetO-Vegfc</italic> mice than DC101 (VEGFR2 inhibitor). Our findings are consistent with other studies that have reported that blockade or loss of VEGFR3 has a greater effect on lymphangiogenesis than blockade or loss of VEGFR2 (<xref ref-type="bibr" rid="bib61">Yao et al., 2014</xref>; <xref ref-type="bibr" rid="bib64">Zarkada et al., 2015</xref>; <xref ref-type="bibr" rid="bib3">Baluk et al., 2005</xref>; <xref ref-type="bibr" rid="bib63">Yuen et al., 2011</xref>).</p><p>LECs arise from multiple different sources. LECs come from pre-existing LECs (<xref ref-type="bibr" rid="bib55">Srinivasan et al., 2007</xref>), blood endothelial cells (BECs) (<xref ref-type="bibr" rid="bib55">Srinivasan et al., 2007</xref>; <xref ref-type="bibr" rid="bib56">Stanczuk et al., 2015</xref>; <xref ref-type="bibr" rid="bib39">Martinez-Corral et al., 2015</xref>), and from an unknown cellular source (<xref ref-type="bibr" rid="bib39">Martinez-Corral et al., 2015</xref>). There is growing evidence that bone marrow-derived cells can also differentiate into LECs. Bone marrow transplantation experiments with GFP-positive donor mice suggest that bone-marrow-derived cells can incorporate into lymphatic vessels (<xref ref-type="bibr" rid="bib49">Religa et al., 2005</xref>; <xref ref-type="bibr" rid="bib24">Jiang et al., 2008</xref>). Additionally, mesenchymal stem cells isolated from bone are reported to express lymphatic markers such as Prox1 and Lyve-1 following exposure to VEGF-C (<xref ref-type="bibr" rid="bib32">Lee et al., 2010</xref>). The origin of bone LECs is not known. Lineage-tracing studies with <italic>Osx-tTA;TetO-Vegfc</italic> mice could reveal whether LECs in bone arise from pre-existing LECs, BECs, or from a different cellular source.</p><p>We found that <italic>Osx-tTA;TetO-Vegfc</italic> mice had more osteoclasts than <italic>Osx-tTA</italic> mice. There are conflicting reports as to whether or not VEGF-C can directly stimulate osteoclast formation. VEGF-C was reported to promote osteoclast formation by one group (<xref ref-type="bibr" rid="bib42">Motokawa et al., 2013</xref>) but not by another (<xref ref-type="bibr" rid="bib65">Zhang et al., 2008</xref>). We found that VEGF-C did not induce or enhance osteoclast formation by RAW264.7 cells (data not shown). We also found that osteoclasts did not express VEGFR2 or VEGFR3 in vivo (data not shown). Therefore, other factors are likely responsible for stimulating osteoclast formation in <italic>Osx-tTA;TetO-Vegfc</italic> mice. Macrophage colony-stimulating factor (M-CSF) is a factor that promotes the development of osteoclasts (<xref ref-type="bibr" rid="bib9">Dai et al., 2002</xref>). It was recently reported that LECs express a high level of M-CSF and that LEC-conditioned media can stimulate osteoclast formation (<xref ref-type="bibr" rid="bib58">Wang et al., 2017a2017</xref>). Importantly, an M-CSF function-blocking antibody inhibited the ability of LEC-conditioned media to promote osteoclast formation (<xref ref-type="bibr" rid="bib59">Wang et al., 2017b</xref>). Therefore, LECs in the bones of <italic>Osx-tTA;TetO-Vegfc</italic> mice may stimulate osteoclast development by secreting M-CSF.</p><p>The precise cause of bone loss in GSD is unclear. A prevailing view in the field is that osteoclasts promote excessive bone resorption in GSD. Osteoclasts have been detected in many different GSD patient samples (<xref ref-type="bibr" rid="bib47">Pazzaglia et al., 1997</xref>; <xref ref-type="bibr" rid="bib1">Avelar et al., 2010</xref>; <xref ref-type="bibr" rid="bib6">Bruder et al., 2009</xref>; <xref ref-type="bibr" rid="bib7">Choma et al., 1987</xref>; <xref ref-type="bibr" rid="bib18">Hammer et al., 2005</xref>; <xref ref-type="bibr" rid="bib20">Hirayama et al., 2001</xref>; <xref ref-type="bibr" rid="bib33">Lehmann et al., 2009</xref>; <xref ref-type="bibr" rid="bib43">Möller et al., 1999</xref>; <xref ref-type="bibr" rid="bib53">Silva, 2011</xref>; <xref ref-type="bibr" rid="bib54">Spieth et al., 1997</xref>; <xref ref-type="bibr" rid="bib48">Poirier, 1968</xref>; <xref ref-type="bibr" rid="bib25">Jones et al., 1958</xref>) and CTX-1 has been reported to be elevated in several patients (<xref ref-type="bibr" rid="bib35">Liu et al., 2016</xref>). Zoledronic acid has been given to GSD patients in an attempt to prevent bone loss (<xref ref-type="bibr" rid="bib1">Avelar et al., 2010</xref>; <xref ref-type="bibr" rid="bib17">Hagendoorn et al., 2006</xref>; <xref ref-type="bibr" rid="bib29">Kuriyama et al., 2010</xref>; <xref ref-type="bibr" rid="bib34">Leite et al., 2013</xref>; <xref ref-type="bibr" rid="bib51">Ruggieri et al., 2011</xref>; <xref ref-type="bibr" rid="bib14">Gem et al., 2014</xref>; <xref ref-type="bibr" rid="bib41">Mignogna et al., 2005</xref>; <xref ref-type="bibr" rid="bib62">Yerganyan et al., 2015</xref>). Indeed, several case reports state that there is no further progression of the disease after the patient is treated with zoledronic acid (<xref ref-type="bibr" rid="bib1">Avelar et al., 2010</xref>; <xref ref-type="bibr" rid="bib29">Kuriyama et al., 2010</xref>; <xref ref-type="bibr" rid="bib14">Gem et al., 2014</xref>; <xref ref-type="bibr" rid="bib41">Mignogna et al., 2005</xref>; <xref ref-type="bibr" rid="bib62">Yerganyan et al., 2015</xref>). However, it is difficult to assess the benefit of zoledronic acid in GSD patients because it is often given in combination with other treatments and it is usually unclear as to whether the osteolytic process was active or inactive at the start of treatment. We found that zoledronic acid attenuated bone loss in <italic>Osx-tTA;TetO-Vegfc</italic> mice. These data indicate that osteoclasts promote the destruction of bone in <italic>Osx-tTA;TetO-Vegfc</italic> mice and warrant further investigation into the effects of osteoclast inhibitors on GSD.</p><p>Several studies have shown that newly formed lymphatic vessels persist following the withdrawal of a growth-promoting stimulus. One study showed that abnormal lymphatic vessels persisted in the airways of <italic>CCSP-rtTA;TetO-Vegfc</italic> mice for up to 19 months after the withdrawal of VEGF-C (<xref ref-type="bibr" rid="bib61">Yao et al., 2014</xref>). Another study showed that abnormal lymphatic vessels persisted in the skin of <italic>K14-rtTA;TetO-Vegfc</italic> mice for up to 6 months after the withdrawal of VEGF-C (<xref ref-type="bibr" rid="bib36">Lohela et al., 2008</xref>). Additionally, it was reported that global inactivation of VEGF-C in adult mice only caused lymphatic vessels in the intestine to atrophy (<xref ref-type="bibr" rid="bib45">Nurmi et al., 2015</xref>). Together, these findings suggest that lymphatic vessels in most tissues do not spontaneously regress following the withdrawal of VEGF-C. We found that newly formed lymphatics in bone, but not in periosseous muscle, disappeared following the withdrawal of VEGF-C. One possible explanation for this finding is that bone lacks lymphatic maintenance factors. An alternative explanation for this finding is that bone possesses lymphatic inhibitory factors whose effects can be overcome by overexpressing VEGF-C. Future experiments will help distinguish between these two possibilities and shed light on the molecular players and pathways that control the patterning of the lymphatic vasculature.</p><p>Transgenic manipulation of the VEGF-C/VEGFR3 signaling pathway has been widely used to investigate the role lymphatics serve in various pathological settings. Transgenic mice that express a soluble version of VEGFR3 have been used to study the pathophysiology of lymphedema (<xref ref-type="bibr" rid="bib40">Mäkinen et al., 2001</xref>; <xref ref-type="bibr" rid="bib52">Rutkowski et al., 2010</xref>), whereas VEGF-C transgenic mice have been used to model pulmonary lymphangiectasia (<xref ref-type="bibr" rid="bib61">Yao et al., 2014</xref>), to study the pathophysiology of chylothorax (<xref ref-type="bibr" rid="bib44">Nitschké et al., 2017</xref>), and to identify the specific function lymphatics serve in inflammation (<xref ref-type="bibr" rid="bib21">Huggenberger et al., 2011</xref>) and cancer (<xref ref-type="bibr" rid="bib38">Mandriota et al., 2001</xref>; <xref ref-type="bibr" rid="bib19">Hirakawa et al., 2007</xref>). We have found that transgenic overexpression of VEGF-C in bone stimulates the formation of bone lymphatics and osteoclast-mediated bone resorption. Importantly, our transgenic mice can be used to further study these processes, which are relevant to the pathogenesis of GSD.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th>Reagent type (species) <break/>or resource</th><th>Designation</th><th>Source or reference</th><th>Identifiers</th><th>Additional information</th></tr></thead><tbody><tr><td>Genetic reagent (<italic>Mus musculus</italic>)</td><td><italic>Osx-tTA</italic></td><td>PMID: 16854976</td><td/><td/></tr><tr><td>Genetic reagent (<italic>Mus musculus</italic>)</td><td><italic>TetO-Vegfc</italic></td><td>PMID: 18988807</td><td/><td/></tr><tr><td>Genetic reagent (<italic>Mus musculus</italic>)</td><td><italic>TetO-Vegfd</italic></td><td>PMID: 27342876</td><td/><td/></tr><tr><td>Antibody</td><td>anti-GFP (chicken polyclonal)</td><td>abcam, ab13970</td><td/><td>(1:1000)</td></tr><tr><td>Antibody</td><td>anti-Lyve-1 (goat polyclonal)</td><td>R and D Systems, AF2125</td><td/><td>(1:250)</td></tr><tr><td>Antibody</td><td>anti-Podoplanin (hamster monoclonal)</td><td>abcam, ab11936</td><td/><td>(1:1000)</td></tr><tr><td>Antibody</td><td>anti-VEGFR2 (rat monoclonal)</td><td>Eli Lily</td><td>DC101</td><td>Function blocking antibody</td></tr><tr><td>Antibody</td><td>anti-VEGFR3 (rat monoclonal)</td><td>Eli Lily</td><td>mF4-31C1</td><td>Function blocking antibody</td></tr><tr><td>Commerical assay, kit</td><td>ELISA kit - CTX-1</td><td>CUSABIO, CSB - E12782M</td><td/><td/></tr><tr><td>Commerical assay, kit</td><td>ELISA kit - VEGF-C</td><td>CUSABIO, CSB - E07361M</td><td/><td/></tr><tr><td>Commerical assay, kit</td><td>TRIzol</td><td>Life Technologies, 15596018</td><td/><td/></tr><tr><td>Commerical assay, kit</td><td>Rneasy RNA Isolation kit</td><td>Qiagen, 74104</td><td/><td/></tr><tr><td>Commerical assay, kit</td><td>cDNA synthesis kit</td><td>BioRad, 74104</td><td/><td/></tr><tr><td>Commerical assay, kit</td><td>2 ml phase lock gel tube</td><td>Quanta, 2302830</td><td/><td/></tr><tr><td>Commerical assay, kit</td><td>beads for tissue homogenizing</td><td>Biospec Products, 11079124zx</td><td/><td/></tr><tr><td>Chemical compound, drug</td><td>Doxycyline</td><td>Sigma Aldrich, D9891</td><td/><td/></tr><tr><td>Chemical compound, drug</td><td>Zoledronic acid</td><td>SAGENT Pharmaceuticals, 801–66</td><td/><td/></tr><tr><td>Software, algorithm</td><td>ImageJ</td><td>ImageJ 1.48 v</td><td/><td/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Mice and genotyping</title><p>The animal experiments described in this manuscript were carried out in accordance with an animal protocol approved by the Institutional Animal Care and Use Committee of UT Southwestern Medical Center. <italic>TetO-Vegfc</italic> mice (<xref ref-type="bibr" rid="bib36">Lohela et al., 2008</xref>) were genotyped with the following primers: 5′-CCAAACCGGGCCCCTCTGCTAAC-3′ and 5′-ACTGTCCCCTGTCCTGGTATTGAG-3′. The PCR product for the transgenic allele was approximately 450 bp. <italic>TetO-Vegfd</italic> mice (<xref ref-type="bibr" rid="bib31">Lammoglia et al., 2016</xref>) were genotyped with the following primers: 5’-GCTCGTTTAGTGAACCGTCAG-3’ and 5’-TGCTCGGATCTGTTGTTCAG-3’. The PCR product for the transgenic allele was approximately 250 bp. <italic>Osx-tTA</italic> mice (<xref ref-type="bibr" rid="bib50">Rodda and McMahon, 2006</xref>) were genotyped with the following primers: 5′-CCTGGAAAATGCTTCTGTCCG-3′, 5′-CAGGGTGTTATAAGCAATCCC-3′, 5′-CAATGGTAGGCTCACTCTGGGAGATGAT​−3′, and 5′-​AACACACACTGGCAGGACTGGCTAGG-3′. The wild-type band was 300 bp and the Cre band was 400 bp.</p></sec><sec id="s4-2"><title>Doxycycline administration</title><p><italic>Osx-tTA</italic> (control) and <italic>Osx-tTA;TetO-Vegfc</italic> littermates received water containing doxycycline (1 mg/ml; Sigma-Aldrich, D9891, St. Louis, MO) and sucrose (5% w/v) from E0.5 to E18.5. Mice were then placed on normal water. For the reversal experiments, <italic>Osx-tTA;TetO-Vegfc</italic> mice were placed back on water containing doxycycline (1 mg/ml) and sucrose (5% w/v). Doxycycline water was replaced three times a week.</p></sec><sec id="s4-3"><title>Therapy studies with mice</title><p>DC101 and mF4-31C1 are rat monoclonal antibodies that block VEGFR2 and VEGFR3, respectively (ImClone/Eli Lilly). P21 <italic>Osx-tTA;TetO-Vegfc</italic> mice were treated with sterile saline (3x/week; i.p.), DC101 (800 μg; 3x/week; i.p.), or mF4-31C1 (800 μg; 3x/week; i.p.) for 2 weeks. To assess the effect of osteoclast inhibition on bone loss, P21 <italic>Osx-tTA;TetO-Vegfc</italic> mice were treated with sterile saline (q.a.d.; i.p.) or zoledronic acid (1.2 μg; q.a.d.; i.p.) for 2 weeks. Mice were randomly assigned to the various treatment groups.</p></sec><sec id="s4-4"><title>Immunohistochemistry</title><p>Slides were deparaffinized with xylene and rehydrated through a descending EtOH series. Endogenous peroxidase activity was blocked by incubating slides with hydrogen peroxide diluted in methanol. Antigen retrieval was performed by incubating slides in a proteinase K solution at 37°C for 5 min. Slides were washed with PBS and then blocked for 1 hr with TBST (TBS +0.2% Tween 20)+20% Aquablock. Tissue sections were incubated overnight with primary antibodies diluted in TBST +5% BSA. The following primary antibodies were used for immunohistochemistry: goat anti-Lyve-1 (R and D Systems; AF2125, Minneapolis, MN), chicken anti-GFP (Abcam; ab13970, Cambridge, MA), and hamster anti-podoplanin (Abcam; ab11936). Slides were washed with TBST and then incubated with HRP conjugated secondary antibodies diluted in TBST +5% BSA. Slides were washed with TBST and antibody binding was detected with DAB (Dako, K3468, Santa Clara, CA).</p></sec><sec id="s4-5"><title>Measuring lymphatic vessel index</title><p>To quantify bone lymphatics, multiple pictures of cortical bone and of the area below the growth plate were analyzed in ImageJ. A grid (19,000 cm<sup>2</sup>) was placed over the pictures and the number of times that gridlines intersected within or on a lymphatic was determined.</p></sec><sec id="s4-6"><title>Tartrate-resistant acid phosphatase (TRAP) staining and analysis</title><p>Bone sections were deparaffinized with xylene, rehydrated through a descending EtOH series, and then placed in pre-warmed TRAP staining solution (TRAP basic incubation media + Fast Red Violet Salt + Napthol AS-MX Phosphate) for 1 hr. Slides were rinsed with water and counterstained with Fast Green for 30 s. Next, slides were rinsed with water, dehydrated through an ascending EtOH series, and cleared in xylene. Pictures were taken with an AmScope FMA050 camera attached to a Nikon Eclipse E600 microscope. The number of osteoclasts per mm bone surface was assessed with ImageJ.</p></sec><sec id="s4-7"><title>ELISA for VEGF-C and CTX-1</title><p>Plasma was collected from mice and commercially available ELISA kits were used to measure the circulating levels of VEGF-C (CUSABIO, #CSB-E07361M, Houston, TX) and CTX-1 (CUSABIO, #CSB-E12782M). A BCA assay was performed to determine the total protein content of each plasma sample. VEGF-C and CTX-1 values were normalized to the total protein content.</p></sec><sec id="s4-8"><title>RNA isolation and quantitative PCR</title><p>Frozen tibias were placed inside an RNase-free bag and crushed with a hammer. The crushed samples were transferred to a tube containing 1 ml of TRIzol (Life Technologies, 15596018, Carlsbad, CA) and 1 ml of beads (Biospec Products, #11079124zx, Bartlesville, OK). The samples were homogenized in a Minibead Beater (Biospec Products). The homogenized lysate was transferred to a 2 ml Phase Lock Gel Tube (Quanta, #2302830) and spun at 12,000 <italic>g</italic> for 5 min. The upper layer of the spun solution was transferred to a Qiagen column and RNA was isolated with an RNeasy kit (Qiagen) according to the manufacturer’s instructions. cDNA was synthesized with an iScript cDNA synthesis kit (BioRad; #74104) according to the manufacturer’s instructions. The following primers were used in SYBR green qPCR reactions to amplify <italic>Vegfc</italic> (5’-TCCCCTGTCCTGGTATTGAG-3’ and 5’-CGAGGTCAAGGCTTTTGAAG-3’) and <italic>beta-actin</italic> (5’-CTGTCGAGTCGCGTCCA-3’ and 5’-ACCCATTCCCACCATCACAC-3’). Relative VEGF-C mRNA levels were calculated by the 2<sup>-ΔΔCT</sup> method.</p></sec><sec id="s4-9"><title>Evans blue dye lymphangiography</title><p>Our lymphangiography experiments were modeled after an approach recently published by Nitschke and colleagues (<xref ref-type="bibr" rid="bib44">Nitschké et al., 2017</xref>). Immediately after euthanasia, the mesenteric lymph node was identified and injected with Evans blue dye (1% w/v). The thoracic cavity was then opened and pictures of the thoracic duct and chest wall were captured with an AmScope FMA050 camera.</p></sec><sec id="s4-10"><title>Assessment of cortical bone</title><p>Fixed bones were scanned using a μCT imaging system (35, Scanco Medical, Bassersdorf, Switzerland). The μCT Evaluation Program (V6.6) was used to measure the volume of the pores in bone and the total volume of the region of interest. Cortical porosity was determined by dividing the total volume of the pores by the total volume of the region of interest. Cortical bone was also assessed histologically. Decalcified bones were sectioned with a microtome and stained with hematoxylin and eosin. Images were captured with an AmScope FMA050 camera attached to a Nikon Eclipse E600 microscope. ImageJ was used to measure the area of the pores in bone and the total area of the region of interest. Cortical porosity was determined by dividing the total area of the pores by the total area of the region of interest.</p></sec><sec id="s4-11"><title>Three-point bending assay</title><p>Peak load at failure was tested in femora using a 3-point bending technique. Femora were placed with the anterior aspect up so that an actuator contacted the bones at mid-diaphysis. A Test Resources DDL200 axial loading machine outfitted with an Interface SMT1-22 force transducer was set to a cross-head displacement rate of 0.1 mm/sec. The femora rested on two supports 5 mm apart.</p></sec><sec id="s4-12"><title>Osteo-assay surface plate</title><p>One ml of primary human LECs (50,000 cells/ml) and one ml of RAW264.7 cells (50,000 cells/ml) were seeded into separate wells of an osteo-assay plate (Corning; #3987, Corning, NY). Recombinant RANKL (final concentration 50 ng/ml) was added to the wells that contained RAW264.7 cells. Cells were cultured at 37°C for 72 hr. Media was aspirated and one ml of 10% bleach was added to each well. Wells were then washed with water and images were captured with an inverted microscope. Image J was used to measure the area resorbed by cells.</p></sec><sec id="s4-13"><title>Statistical analysis</title><p>Data were analyzed using GraphPad Prism statistical analysis software (Version 7.0). All results are expressed as mean ± SD. The number of mice in each group is indicated in the figure legends (n = number of mice). For experiments with two groups, unpaired student’s T-tests were performed to test means for significance. For experiments with more than two groups, differences were assessed by ANOVA followed by Dunnett’s multiple comparisons test. Data were considered significant at p&lt;0.05.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank Jack Kelly (President, Lymphangiomatosis and Gorham’s Disease Alliance) and Tiffany Ferry (President, The Lymphatic Malformation Institute) for their valuable comments on the project. We also thank Rolf Brekken and members of JMST for their comments on the manuscript. Funding: This work was supported by the Department of Surgery at UT Southwestern Medical Center (MTD) and by a grant from The Lymphatic Malformation Institute (MTD). </p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf3"><p>Reviewing editor, <italic>eLife</italic></p></fn><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>During preparation of the manuscript, B Pytowski was an employee of Eli Lilly and continues to hold stock in the company.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Investigation, Writing—review and editing</p></fn><fn fn-type="con" id="con2"><p>Investigation</p></fn><fn fn-type="con" id="con3"><p>Investigation</p></fn><fn fn-type="con" id="con4"><p>Investigation</p></fn><fn fn-type="con" id="con5"><p>Investigation</p></fn><fn fn-type="con" id="con6"><p>Investigation</p></fn><fn fn-type="con" id="con7"><p>Resources</p></fn><fn fn-type="con" id="con8"><p>Resources</p></fn><fn fn-type="con" id="con9"><p>Resources, Writing—review and editing</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Formal analysis, Supervision, Investigation, Methodology, Writing—original draft, Writing—review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: The animal experiments described in this manuscript were carried out in accordance with animal protocols (2014-0031 and 2016-101510) approved by the Institutional Animal Care and Use Committee of UT Southwestern Medical Center.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><object-id pub-id-type="doi">10.7554/eLife.34323.016</object-id><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-34323-transrepform-v2.docx"/></supplementary-material></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avelar</surname> <given-names>RL</given-names></name><name><surname>Martins</surname> <given-names>VB</given-names></name><name><surname>Antunes</surname> <given-names>AA</given-names></name><name><surname>de Oliveira Neto</surname> <given-names>PJ</given-names></name><name><surname>Andrade</surname> <given-names>ES</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Use of zoledronic acid in the treatment of Gorham's disease</article-title><source>International Journal of Pediatric Otorhinolaryngology</source><volume>74</volume><fpage>319</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1016/j.ijporl.2009.12.007</pub-id><pub-id pub-id-type="pmid">20074817</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baldwin</surname> <given-names>ME</given-names></name><name><surname>Catimel</surname> <given-names>B</given-names></name><name><surname>Nice</surname> <given-names>EC</given-names></name><name><surname>Roufail</surname> <given-names>S</given-names></name><name><surname>Hall</surname> <given-names>NE</given-names></name><name><surname>Stenvers</surname> <given-names>KL</given-names></name><name><surname>Karkkainen</surname> <given-names>MJ</given-names></name><name><surname>Alitalo</surname> <given-names>K</given-names></name><name><surname>Stacker</surname> <given-names>SA</given-names></name><name><surname>Achen</surname> <given-names>MG</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>The specificity of receptor binding by vascular endothelial growth factor-d is different in mouse and man</article-title><source>Journal of Biological Chemistry</source><volume>276</volume><fpage>19166</fpage><lpage>19171</lpage><pub-id pub-id-type="doi">10.1074/jbc.M100097200</pub-id><pub-id pub-id-type="pmid">11279005</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baluk</surname> <given-names>P</given-names></name><name><surname>Tammela</surname> <given-names>T</given-names></name><name><surname>Ator</surname> <given-names>E</given-names></name><name><surname>Lyubynska</surname> <given-names>N</given-names></name><name><surname>Achen</surname> <given-names>MG</given-names></name><name><surname>Hicklin</surname> <given-names>DJ</given-names></name><name><surname>Jeltsch</surname> <given-names>M</given-names></name><name><surname>Petrova</surname> <given-names>TV</given-names></name><name><surname>Pytowski</surname> <given-names>B</given-names></name><name><surname>Stacker</surname> <given-names>SA</given-names></name><name><surname>Ylä-Herttuala</surname> <given-names>S</given-names></name><name><surname>Jackson</surname> <given-names>DG</given-names></name><name><surname>Alitalo</surname> <given-names>K</given-names></name><name><surname>McDonald</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation</article-title><source>Journal of Clinical Investigation</source><volume>115</volume><fpage>247</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1172/JCI200522037</pub-id><pub-id pub-id-type="pmid">15668734</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baud</surname> <given-names>J</given-names></name><name><surname>Lomri</surname> <given-names>A</given-names></name><name><surname>Graber</surname> <given-names>D</given-names></name><name><surname>Bikfalvi</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The therapeutic response in Gorham's syndrome to the beta-blocking agent propranolol is correlated to VEGF-A, but not to VEGF-C or FLT1 expression</article-title><source>BMC Research Notes</source><volume>8</volume><elocation-id>333</elocation-id><pub-id pub-id-type="doi">10.1186/s13104-015-1259-9</pub-id><pub-id pub-id-type="pmid">26238450</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brodszki</surname> <given-names>N</given-names></name><name><surname>Länsberg</surname> <given-names>JK</given-names></name><name><surname>Dictor</surname> <given-names>M</given-names></name><name><surname>Gyllstedt</surname> <given-names>E</given-names></name><name><surname>Ewers</surname> <given-names>SB</given-names></name><name><surname>Larsson</surname> <given-names>MK</given-names></name><name><surname>Eklund</surname> <given-names>EA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A novel treatment approach for paediatric gorham-stout syndrome with chylothorax</article-title><source>Acta Paediatrica</source><volume>100</volume><fpage>1448</fpage><lpage>1453</lpage><pub-id pub-id-type="doi">10.1111/j.1651-2227.2011.02361.x</pub-id><pub-id pub-id-type="pmid">21605166</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruder</surname> <given-names>E</given-names></name><name><surname>Perez-Atayde</surname> <given-names>AR</given-names></name><name><surname>Jundt</surname> <given-names>G</given-names></name><name><surname>Alomari</surname> <given-names>AI</given-names></name><name><surname>Rischewski</surname> <given-names>J</given-names></name><name><surname>Fishman</surname> <given-names>SJ</given-names></name><name><surname>Mulliken</surname> <given-names>JB</given-names></name><name><surname>Kozakewich</surname> <given-names>HP</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Vascular lesions of bone in children, adolescents, and young adults. A clinicopathologic reappraisal and application of the ISSVA classification</article-title><source>Virchows Archiv</source><volume>454</volume><fpage>161</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1007/s00428-008-0709-3</pub-id><pub-id pub-id-type="pmid">19107514</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choma</surname> <given-names>ND</given-names></name><name><surname>Biscotti</surname> <given-names>CV</given-names></name><name><surname>Bauer</surname> <given-names>TW</given-names></name><name><surname>Mehta</surname> <given-names>AC</given-names></name><name><surname>Licata</surname> <given-names>AA</given-names></name></person-group><year iso-8601-date="1987">1987</year><article-title>Gorham's syndrome: a case report and review of the literature</article-title><source>The American Journal of Medicine</source><volume>83</volume><fpage>1151</fpage><lpage>1156</lpage><pub-id pub-id-type="doi">10.1016/0002-9343(87)90959-4</pub-id><pub-id pub-id-type="pmid">3332570</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clézardin</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mechanisms of action of bisphosphonates in oncology: a scientific concept evolving from antiresorptive to anticancer activities</article-title><source>BoneKEy Reports</source><volume>2</volume><elocation-id>267</elocation-id><pub-id pub-id-type="doi">10.1038/bonekey.2013.1</pub-id><pub-id pub-id-type="pmid">24422040</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname> <given-names>XM</given-names></name><name><surname>Ryan</surname> <given-names>GR</given-names></name><name><surname>Hapel</surname> <given-names>AJ</given-names></name><name><surname>Dominguez</surname> <given-names>MG</given-names></name><name><surname>Russell</surname> <given-names>RG</given-names></name><name><surname>Kapp</surname> <given-names>S</given-names></name><name><surname>Sylvestre</surname> <given-names>V</given-names></name><name><surname>Stanley</surname> <given-names>ER</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects</article-title><source>Blood</source><volume>99</volume><fpage>111</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1182/blood.V99.1.111</pub-id><pub-id pub-id-type="pmid">11756160</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dellinger</surname> <given-names>MT</given-names></name><name><surname>Garg</surname> <given-names>N</given-names></name><name><surname>Olsen</surname> <given-names>BR</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Viewpoints on vessels and vanishing bones in Gorham-Stout disease</article-title><source>Bone</source><volume>63</volume><fpage>47</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2014.02.011</pub-id><pub-id pub-id-type="pmid">24583233</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dellinger</surname> <given-names>MT</given-names></name><name><surname>Hunter</surname> <given-names>RJ</given-names></name><name><surname>Bernas</surname> <given-names>MJ</given-names></name><name><surname>Witte</surname> <given-names>MH</given-names></name><name><surname>Erickson</surname> <given-names>RP</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Chy-3 mice are Vegfc haploinsufficient and exhibit defective dermal superficial to deep lymphatic transition and dermal lymphatic hypoplasia</article-title><source>Developmental Dynamics</source><volume>236</volume><fpage>2346</fpage><lpage>2355</lpage><pub-id pub-id-type="doi">10.1002/dvdy.21208</pub-id><pub-id pub-id-type="pmid">17584866</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname> <given-names>JR</given-names></name><name><surname>Williams</surname> <given-names>K</given-names></name><name><surname>Kindblom</surname> <given-names>LG</given-names></name><name><surname>Meis-Kindblom</surname> <given-names>JM</given-names></name><name><surname>Hogendoorn</surname> <given-names>PC</given-names></name><name><surname>Hughes</surname> <given-names>D</given-names></name><name><surname>Forsyth</surname> <given-names>RG</given-names></name><name><surname>Jackson</surname> <given-names>D</given-names></name><name><surname>Athanasou</surname> <given-names>NA</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Lymphatics and bone</article-title><source>Human Pathology</source><volume>39</volume><fpage>49</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/j.humpath.2007.04.022</pub-id><pub-id pub-id-type="pmid">17904616</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garnero</surname> <given-names>P</given-names></name><name><surname>Ferreras</surname> <given-names>M</given-names></name><name><surname>Karsdal</surname> <given-names>MA</given-names></name><name><surname>Nicamhlaoibh</surname> <given-names>R</given-names></name><name><surname>Risteli</surname> <given-names>J</given-names></name><name><surname>Borel</surname> <given-names>O</given-names></name><name><surname>Qvist</surname> <given-names>P</given-names></name><name><surname>Delmas</surname> <given-names>PD</given-names></name><name><surname>Foged</surname> <given-names>NT</given-names></name><name><surname>Delaissé</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation</article-title><source>Journal of Bone and Mineral Research</source><volume>18</volume><fpage>859</fpage><lpage>867</lpage><pub-id pub-id-type="doi">10.1359/jbmr.2003.18.5.859</pub-id><pub-id pub-id-type="pmid">12733725</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gem</surname> <given-names>M</given-names></name><name><surname>Özkul</surname> <given-names>E</given-names></name><name><surname>Arslan</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Gorham-Stout's disease in the metatarsus: a case report</article-title><source>Acta Orthopaedica Et Traumatologica Turcica</source><volume>48</volume><fpage>467</fpage><lpage>471</lpage><pub-id pub-id-type="doi">10.3944/AOTT.2014.13.0132</pub-id><pub-id pub-id-type="pmid">25230274</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorham</surname> <given-names>LW</given-names></name><name><surname>Stout</surname> <given-names>AP</given-names></name></person-group><year iso-8601-date="1955">1955</year><article-title>Massive osteolysis (acute spontaneous absorption of bone, phantom bone, disappearing bone); its relation to hemangiomatosis</article-title><source>The Journal of Bone and Joint Surgery. American Volume</source><volume>37-A</volume><fpage>985</fpage><lpage>1004</lpage><pub-id pub-id-type="doi">10.2106/00004623-195537050-00008</pub-id><pub-id pub-id-type="pmid">13263344</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorham</surname> <given-names>LW</given-names></name><name><surname>Wright</surname> <given-names>AW</given-names></name><name><surname>Shultz</surname> <given-names>HH</given-names></name><name><surname>Maxon</surname> <given-names>FC</given-names></name></person-group><year iso-8601-date="1954">1954</year><article-title>Disappearing bones: a rare form of massive osteolysis; report of two cases, one with autopsy findings</article-title><source>The American Journal of Medicine</source><volume>17</volume><fpage>674</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1016/0002-9343(54)90027-3</pub-id><pub-id pub-id-type="pmid">13207148</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hagendoorn</surname> <given-names>J</given-names></name><name><surname>Padera</surname> <given-names>TP</given-names></name><name><surname>Yock</surname> <given-names>TI</given-names></name><name><surname>Nielsen</surname> <given-names>GP</given-names></name><name><surname>di Tomaso</surname> <given-names>E</given-names></name><name><surname>Duda</surname> <given-names>DG</given-names></name><name><surname>Delaney</surname> <given-names>TF</given-names></name><name><surname>Gaissert</surname> <given-names>HA</given-names></name><name><surname>Pearce</surname> <given-names>J</given-names></name><name><surname>Rosenberg</surname> <given-names>AE</given-names></name><name><surname>Jain</surname> <given-names>RK</given-names></name><name><surname>Ebb</surname> <given-names>DH</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Platelet-derived growth factor receptor-beta in Gorham's disease</article-title><source>Nature Clinical Practice Oncology</source><volume>3</volume><fpage>693</fpage><lpage>697</lpage><pub-id pub-id-type="doi">10.1038/ncponc0660</pub-id><pub-id pub-id-type="pmid">17139320</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hammer</surname> <given-names>F</given-names></name><name><surname>Kenn</surname> <given-names>W</given-names></name><name><surname>Wesselmann</surname> <given-names>U</given-names></name><name><surname>Hofbauer</surname> <given-names>LC</given-names></name><name><surname>Delling</surname> <given-names>G</given-names></name><name><surname>Allolio</surname> <given-names>B</given-names></name><name><surname>Arlt</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Gorham-Stout disease--stabilization during bisphosphonate treatment</article-title><source>Journal of Bone and Mineral Research</source><volume>20</volume><fpage>350</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1359/JBMR.041113</pub-id><pub-id pub-id-type="pmid">15647829</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirakawa</surname> <given-names>S</given-names></name><name><surname>Brown</surname> <given-names>LF</given-names></name><name><surname>Kodama</surname> <given-names>S</given-names></name><name><surname>Paavonen</surname> <given-names>K</given-names></name><name><surname>Alitalo</surname> <given-names>K</given-names></name><name><surname>Detmar</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites</article-title><source>Blood</source><volume>109</volume><fpage>1010</fpage><lpage>1017</lpage><pub-id pub-id-type="doi">10.1182/blood-2006-05-021758</pub-id><pub-id pub-id-type="pmid">17032920</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirayama</surname> <given-names>T</given-names></name><name><surname>Sabokbar</surname> <given-names>A</given-names></name><name><surname>Itonaga</surname> <given-names>I</given-names></name><name><surname>Watt-Smith</surname> <given-names>S</given-names></name><name><surname>Athanasou</surname> <given-names>NA</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Cellular and humoral mechanisms of osteoclast formation and bone resorption in Gorham-Stout disease</article-title><source>The Journal of Pathology</source><volume>195</volume><fpage>624</fpage><lpage>630</lpage><pub-id pub-id-type="doi">10.1002/path.989</pub-id><pub-id pub-id-type="pmid">11745700</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huggenberger</surname> <given-names>R</given-names></name><name><surname>Siddiqui</surname> <given-names>SS</given-names></name><name><surname>Brander</surname> <given-names>D</given-names></name><name><surname>Ullmann</surname> <given-names>S</given-names></name><name><surname>Zimmermann</surname> <given-names>K</given-names></name><name><surname>Antsiferova</surname> <given-names>M</given-names></name><name><surname>Werner</surname> <given-names>S</given-names></name><name><surname>Alitalo</surname> <given-names>K</given-names></name><name><surname>Detmar</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>An important role of lymphatic vessel activation in limiting acute inflammation</article-title><source>Blood</source><volume>117</volume><fpage>4667</fpage><lpage>4678</lpage><pub-id pub-id-type="doi">10.1182/blood-2010-10-316356</pub-id><pub-id pub-id-type="pmid">21364190</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname> <given-names>JBS</given-names></name></person-group><year iso-8601-date="1838">1838</year><article-title>A boneless arm</article-title><source>Boston Med. and Surg. J</source><volume>18</volume><fpage>368</fpage><lpage>369</lpage></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeltsch</surname> <given-names>M</given-names></name><name><surname>Kaipainen</surname> <given-names>A</given-names></name><name><surname>Joukov</surname> <given-names>V</given-names></name><name><surname>Meng</surname> <given-names>X</given-names></name><name><surname>Lakso</surname> <given-names>M</given-names></name><name><surname>Rauvala</surname> <given-names>H</given-names></name><name><surname>Swartz</surname> <given-names>M</given-names></name><name><surname>Fukumura</surname> <given-names>D</given-names></name><name><surname>Jain</surname> <given-names>RK</given-names></name><name><surname>Alitalo</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Hyperplasia of lymphatic vessels in VEGF-C transgenic mice</article-title><source>Science</source><volume>276</volume><fpage>1423</fpage><lpage>1425</lpage><pub-id pub-id-type="doi">10.1126/science.276.5317.1423</pub-id><pub-id pub-id-type="pmid">9162011</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname> <given-names>S</given-names></name><name><surname>Bailey</surname> <given-names>AS</given-names></name><name><surname>Goldman</surname> <given-names>DC</given-names></name><name><surname>Swain</surname> <given-names>JR</given-names></name><name><surname>Wong</surname> <given-names>MH</given-names></name><name><surname>Streeter</surname> <given-names>PR</given-names></name><name><surname>Fleming</surname> <given-names>WH</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Hematopoietic stem cells contribute to lymphatic endothelium</article-title><source>PLoS One</source><volume>3</volume><elocation-id>e3812</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0003812</pub-id><pub-id pub-id-type="pmid">19043576</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname> <given-names>GB</given-names></name><name><surname>Midgley</surname> <given-names>RL</given-names></name><name><surname>Smith</surname> <given-names>GS</given-names></name></person-group><year iso-8601-date="1958">1958</year><article-title>Massive osteolysis: disappearing bones</article-title><source>The Journal of Bone and Joint Surgery. British volume</source><volume>40-B</volume><fpage>494</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1302/0301-620X.40B3.494</pub-id><pub-id pub-id-type="pmid">13575463</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joukov</surname> <given-names>V</given-names></name><name><surname>Pajusola</surname> <given-names>K</given-names></name><name><surname>Kaipainen</surname> <given-names>A</given-names></name><name><surname>Chilov</surname> <given-names>D</given-names></name><name><surname>Lahtinen</surname> <given-names>I</given-names></name><name><surname>Kukk</surname> <given-names>E</given-names></name><name><surname>Saksela</surname> <given-names>O</given-names></name><name><surname>Kalkkinen</surname> <given-names>N</given-names></name><name><surname>Alitalo</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases</article-title><source>The EMBO Journal</source><volume>15</volume><elocation-id>1751</elocation-id><pub-id pub-id-type="pmid">8612600</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joukov</surname> <given-names>V</given-names></name><name><surname>Sorsa</surname> <given-names>T</given-names></name><name><surname>Kumar</surname> <given-names>V</given-names></name><name><surname>Jeltsch</surname> <given-names>M</given-names></name><name><surname>Claesson-Welsh</surname> <given-names>L</given-names></name><name><surname>Cao</surname> <given-names>Y</given-names></name><name><surname>Saksela</surname> <given-names>O</given-names></name><name><surname>Kalkkinen</surname> <given-names>N</given-names></name><name><surname>Alitalo</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Proteolytic processing regulates receptor specificity and activity of VEGF-C</article-title><source>The EMBO Journal</source><volume>16</volume><fpage>3898</fpage><lpage>3911</lpage><pub-id pub-id-type="doi">10.1093/emboj/16.13.3898</pub-id><pub-id pub-id-type="pmid">9233800</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karkkainen</surname> <given-names>MJ</given-names></name><name><surname>Haiko</surname> <given-names>P</given-names></name><name><surname>Sainio</surname> <given-names>K</given-names></name><name><surname>Partanen</surname> <given-names>J</given-names></name><name><surname>Taipale</surname> <given-names>J</given-names></name><name><surname>Petrova</surname> <given-names>TV</given-names></name><name><surname>Jeltsch</surname> <given-names>M</given-names></name><name><surname>Jackson</surname> <given-names>DG</given-names></name><name><surname>Talikka</surname> <given-names>M</given-names></name><name><surname>Rauvala</surname> <given-names>H</given-names></name><name><surname>Betsholtz</surname> <given-names>C</given-names></name><name><surname>Alitalo</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins</article-title><source>Nature Immunology</source><volume>5</volume><fpage>74</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1038/ni1013</pub-id><pub-id pub-id-type="pmid">14634646</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuriyama</surname> <given-names>DK</given-names></name><name><surname>McElligott</surname> <given-names>SC</given-names></name><name><surname>Glaser</surname> <given-names>DW</given-names></name><name><surname>Thompson</surname> <given-names>KS</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Treatment of Gorham-Stout disease with zoledronic acid and interferon-α: a case report and literature review</article-title><source>Journal of Pediatric Hematology/Oncology</source><volume>32</volume><fpage>579</fpage><lpage>584</lpage><pub-id pub-id-type="doi">10.1097/MPH.0b013e3181edb464</pub-id><pub-id pub-id-type="pmid">20962674</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lala</surname> <given-names>S</given-names></name><name><surname>Mulliken</surname> <given-names>JB</given-names></name><name><surname>Alomari</surname> <given-names>AI</given-names></name><name><surname>Fishman</surname> <given-names>SJ</given-names></name><name><surname>Kozakewich</surname> <given-names>HP</given-names></name><name><surname>Chaudry</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Gorham-Stout disease and generalized lymphatic anomaly--clinical, radiologic, and histologic differentiation</article-title><source>Skeletal Radiology</source><volume>42</volume><fpage>917</fpage><lpage>924</lpage><pub-id pub-id-type="doi">10.1007/s00256-012-1565-4</pub-id><pub-id pub-id-type="pmid">23371338</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lammoglia</surname> <given-names>GM</given-names></name><name><surname>Van Zandt</surname> <given-names>CE</given-names></name><name><surname>Galvan</surname> <given-names>DX</given-names></name><name><surname>Orozco</surname> <given-names>JL</given-names></name><name><surname>Dellinger</surname> <given-names>MT</given-names></name><name><surname>Rutkowski</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Hyperplasia, de novo lymphangiogenesis, and lymphatic regression in mice with tissue-specific, inducible overexpression of murine VEGF-D</article-title><source>American Journal of Physiology-Heart and Circulatory Physiology</source><volume>311</volume><fpage>H384</fpage><lpage>H394</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00208.2016</pub-id><pub-id pub-id-type="pmid">27342876</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>JY</given-names></name><name><surname>Park</surname> <given-names>C</given-names></name><name><surname>Cho</surname> <given-names>YP</given-names></name><name><surname>Lee</surname> <given-names>E</given-names></name><name><surname>Kim</surname> <given-names>H</given-names></name><name><surname>Kim</surname> <given-names>P</given-names></name><name><surname>Yun</surname> <given-names>SH</given-names></name><name><surname>Yoon</surname> <given-names>YS</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Podoplanin-expressing cells derived from bone marrow play a crucial role in postnatal lymphatic neovascularization</article-title><source>Circulation</source><volume>122</volume><fpage>1413</fpage><lpage>1425</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.110.941468</pub-id><pub-id pub-id-type="pmid">20855662</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lehmann</surname> <given-names>G</given-names></name><name><surname>Pfeil</surname> <given-names>A</given-names></name><name><surname>Böttcher</surname> <given-names>J</given-names></name><name><surname>Kaiser</surname> <given-names>WA</given-names></name><name><surname>Füller</surname> <given-names>J</given-names></name><name><surname>Hein</surname> <given-names>G</given-names></name><name><surname>Wolf</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Benefit of a 17-year long-term bisphosphonate therapy in a patient with Gorham-Stout syndrome</article-title><source>Archives of Orthopaedic and Trauma Surgery</source><volume>129</volume><fpage>967</fpage><lpage>972</lpage><pub-id pub-id-type="doi">10.1007/s00402-008-0742-3</pub-id><pub-id pub-id-type="pmid">18807053</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leite</surname> <given-names>I</given-names></name><name><surname>Hernández-Martín</surname> <given-names>A</given-names></name><name><surname>Colmenero</surname> <given-names>I</given-names></name><name><surname>López-Gutiérrez</surname> <given-names>JC</given-names></name><name><surname>Torrelo</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Invasive lymphatic malformation (gorham-stout) of the pelvis with prominent skin involvement</article-title><source>Pediatric Dermatology</source><volume>30</volume><fpage>374</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1111/j.1525-1470.2012.01814.x</pub-id><pub-id pub-id-type="pmid">22823281</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Zhong</surname> <given-names>DR</given-names></name><name><surname>Zhou</surname> <given-names>PR</given-names></name><name><surname>Lv</surname> <given-names>F</given-names></name><name><surname>Ma</surname> <given-names>DD</given-names></name><name><surname>Xia</surname> <given-names>WB</given-names></name><name><surname>Jiang</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>O</given-names></name><name><surname>Xing</surname> <given-names>XP</given-names></name><name><surname>Li</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Gorham-Stout disease: radiological, histological, and clinical features of 12 cases and review of literature</article-title><source>Clinical Rheumatology</source><volume>35</volume><fpage>813</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1007/s10067-014-2780-2</pub-id><pub-id pub-id-type="pmid">25227772</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lohela</surname> <given-names>M</given-names></name><name><surname>Heloterä</surname> <given-names>H</given-names></name><name><surname>Haiko</surname> <given-names>P</given-names></name><name><surname>Dumont</surname> <given-names>DJ</given-names></name><name><surname>Alitalo</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Transgenic induction of vascular endothelial growth factor-C is strongly angiogenic in mouse embryos but leads to persistent lymphatic hyperplasia in adult tissues</article-title><source>The American Journal of Pathology</source><volume>173</volume><fpage>1891</fpage><lpage>1901</lpage><pub-id pub-id-type="doi">10.2353/ajpath.2008.080378</pub-id><pub-id pub-id-type="pmid">18988807</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ludwig</surname> <given-names>KF</given-names></name><name><surname>Slone</surname> <given-names>T</given-names></name><name><surname>Cederberg</surname> <given-names>KB</given-names></name><name><surname>Silva</surname> <given-names>AT</given-names></name><name><surname>Dellinger</surname> <given-names>MT</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A new case and review ofchylothorax in generalized lymphatic anomaly and Gorham-Stout disease</article-title><source>Lymphology</source><volume>49</volume><fpage>73</fpage><lpage>84</lpage></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mandriota</surname> <given-names>SJ</given-names></name><name><surname>Jussila</surname> <given-names>L</given-names></name><name><surname>Jeltsch</surname> <given-names>M</given-names></name><name><surname>Compagni</surname> <given-names>A</given-names></name><name><surname>Baetens</surname> <given-names>D</given-names></name><name><surname>Prevo</surname> <given-names>R</given-names></name><name><surname>Banerji</surname> <given-names>S</given-names></name><name><surname>Huarte</surname> <given-names>J</given-names></name><name><surname>Montesano</surname> <given-names>R</given-names></name><name><surname>Jackson</surname> <given-names>DG</given-names></name><name><surname>Orci</surname> <given-names>L</given-names></name><name><surname>Alitalo</surname> <given-names>K</given-names></name><name><surname>Christofori</surname> <given-names>G</given-names></name><name><surname>Pepper</surname> <given-names>MS</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis</article-title><source>The EMBO Journal</source><volume>20</volume><fpage>672</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1093/emboj/20.4.672</pub-id><pub-id pub-id-type="pmid">11179212</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Corral</surname> <given-names>I</given-names></name><name><surname>Ulvmar</surname> <given-names>MH</given-names></name><name><surname>Stanczuk</surname> <given-names>L</given-names></name><name><surname>Tatin</surname> <given-names>F</given-names></name><name><surname>Kizhatil</surname> <given-names>K</given-names></name><name><surname>John</surname> <given-names>SW</given-names></name><name><surname>Alitalo</surname> <given-names>K</given-names></name><name><surname>Ortega</surname> <given-names>S</given-names></name><name><surname>Makinen</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Nonvenous origin of dermal lymphatic vasculature</article-title><source>Circulation Research</source><volume>116</volume><fpage>1649</fpage><lpage>1654</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.306170</pub-id><pub-id pub-id-type="pmid">25737499</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mäkinen</surname> <given-names>T</given-names></name><name><surname>Jussila</surname> <given-names>L</given-names></name><name><surname>Veikkola</surname> <given-names>T</given-names></name><name><surname>Karpanen</surname> <given-names>T</given-names></name><name><surname>Kettunen</surname> <given-names>MI</given-names></name><name><surname>Pulkkanen</surname> <given-names>KJ</given-names></name><name><surname>Kauppinen</surname> <given-names>R</given-names></name><name><surname>Jackson</surname> <given-names>DG</given-names></name><name><surname>Kubo</surname> <given-names>H</given-names></name><name><surname>Nishikawa</surname> <given-names>S</given-names></name><name><surname>Ylä-Herttuala</surname> <given-names>S</given-names></name><name><surname>Alitalo</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3</article-title><source>Nature Medicine</source><volume>7</volume><fpage>199</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1038/84651</pub-id><pub-id pub-id-type="pmid">11175851</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mignogna</surname> <given-names>MD</given-names></name><name><surname>Fedele</surname> <given-names>S</given-names></name><name><surname>Lo Russo</surname> <given-names>L</given-names></name><name><surname>Ciccarelli</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Treatment of Gorham's disease with zoledronic acid</article-title><source>Oral Oncology</source><volume>41</volume><fpage>747</fpage><lpage>750</lpage><pub-id pub-id-type="doi">10.1016/j.oraloncology.2005.04.007</pub-id><pub-id pub-id-type="pmid">15979927</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motokawa</surname> <given-names>M</given-names></name><name><surname>Tsuka</surname> <given-names>N</given-names></name><name><surname>Kaku</surname> <given-names>M</given-names></name><name><surname>Kawata</surname> <given-names>T</given-names></name><name><surname>Fujita</surname> <given-names>T</given-names></name><name><surname>Ohtani</surname> <given-names>J</given-names></name><name><surname>Matsuda</surname> <given-names>Y</given-names></name><name><surname>Terao</surname> <given-names>A</given-names></name><name><surname>Tanne</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Effects of vascular endothelial growth factor-C and -D on osteoclast differentiation and function in human peripheral blood mononuclear cells</article-title><source>Archives of oral biology</source><volume>58</volume><pub-id pub-id-type="doi">10.1016/j.archoralbio.2012.06.010</pub-id><pub-id pub-id-type="pmid">22771550</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Möller</surname> <given-names>G</given-names></name><name><surname>Priemel</surname> <given-names>M</given-names></name><name><surname>Amling</surname> <given-names>M</given-names></name><name><surname>Werner</surname> <given-names>M</given-names></name><name><surname>Kuhlmey</surname> <given-names>AS</given-names></name><name><surname>Delling</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>The Gorham-Stout syndrome (Gorham's massive osteolysis). A report of six cases with histopathological findings</article-title><source>The Journal of Bone and Joint Surgery. British Volume</source><volume>81</volume><fpage>501</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1302/0301-620X.81B3.9468</pub-id><pub-id pub-id-type="pmid">10872375</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nitschké</surname> <given-names>M</given-names></name><name><surname>Bell</surname> <given-names>A</given-names></name><name><surname>Karaman</surname> <given-names>S</given-names></name><name><surname>Amouzgar</surname> <given-names>M</given-names></name><name><surname>Rutkowski</surname> <given-names>JM</given-names></name><name><surname>Scherer</surname> <given-names>PE</given-names></name><name><surname>Alitalo</surname> <given-names>K</given-names></name><name><surname>McDonald</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Retrograde lymph flow leads to chylothorax in transgenic mice with lymphatic malformations</article-title><source>The American Journal of Pathology</source><volume>187</volume><fpage>1984</fpage><lpage>1997</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2017.05.009</pub-id><pub-id pub-id-type="pmid">28683257</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nurmi</surname> <given-names>H</given-names></name><name><surname>Saharinen</surname> <given-names>P</given-names></name><name><surname>Zarkada</surname> <given-names>G</given-names></name><name><surname>Zheng</surname> <given-names>W</given-names></name><name><surname>Robciuc</surname> <given-names>MR</given-names></name><name><surname>Alitalo</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>VEGF-C is required for intestinal lymphatic vessel maintenance and lipid absorption</article-title><source>EMBO Molecular Medicine</source><volume>7</volume><fpage>1418</fpage><lpage>1425</lpage><pub-id pub-id-type="doi">10.15252/emmm.201505731</pub-id><pub-id pub-id-type="pmid">26459520</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozeki</surname> <given-names>M</given-names></name><name><surname>Fujino</surname> <given-names>A</given-names></name><name><surname>Matsuoka</surname> <given-names>K</given-names></name><name><surname>Nosaka</surname> <given-names>S</given-names></name><name><surname>Kuroda</surname> <given-names>T</given-names></name><name><surname>Fukao</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Clinical features and prognosis of generalized lymphatic anomaly, kaposiform lymphangiomatosis, and gorham-stout disease</article-title><source>Pediatric Blood &amp; Cancer</source><volume>63</volume><fpage>832</fpage><lpage>838</lpage><pub-id pub-id-type="doi">10.1002/pbc.25914</pub-id><pub-id pub-id-type="pmid">26806875</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pazzaglia</surname> <given-names>UE</given-names></name><name><surname>Andrini</surname> <given-names>L</given-names></name><name><surname>Bonato</surname> <given-names>M</given-names></name><name><surname>Leutner</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Pathology of disappearing bone disease: a case report with immunohistochemical study</article-title><source>International Orthopaedics</source><volume>21</volume><fpage>303</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1007/s002640050173</pub-id><pub-id pub-id-type="pmid">9476159</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poirier</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="1968">1968</year><article-title>Massive osteolysis of the humerus treated by resection and prosthetic replacement</article-title><source>The Journal of Bone and Joint Surgery. British Volume</source><volume>50</volume><fpage>158</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1302/0301-620X.50B1.158</pub-id><pub-id pub-id-type="pmid">5641589</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Religa</surname> <given-names>P</given-names></name><name><surname>Cao</surname> <given-names>R</given-names></name><name><surname>Bjorndahl</surname> <given-names>M</given-names></name><name><surname>Zhou</surname> <given-names>Z</given-names></name><name><surname>Zhu</surname> <given-names>Z</given-names></name><name><surname>Cao</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Presence of bone marrow-derived circulating progenitor endothelial cells in the newly formed lymphatic vessels</article-title><source>Blood</source><volume>106</volume><fpage>4184</fpage><lpage>4190</lpage><pub-id pub-id-type="doi">10.1182/blood-2005-01-0226</pub-id><pub-id pub-id-type="pmid">16141354</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodda</surname> <given-names>SJ</given-names></name><name><surname>McMahon</surname> <given-names>AP</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors</article-title><source>Development</source><volume>133</volume><fpage>3231</fpage><lpage>3244</lpage><pub-id pub-id-type="doi">10.1242/dev.02480</pub-id><pub-id pub-id-type="pmid">16854976</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruggieri</surname> <given-names>P</given-names></name><name><surname>Montalti</surname> <given-names>M</given-names></name><name><surname>Angelini</surname> <given-names>A</given-names></name><name><surname>Alberghini</surname> <given-names>M</given-names></name><name><surname>Mercuri</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Gorham-Stout disease: the experience of the Rizzoli Institute and review of the literature</article-title><source>Skeletal Radiology</source><volume>40</volume><fpage>1391</fpage><lpage>1397</lpage><pub-id pub-id-type="doi">10.1007/s00256-010-1051-9</pub-id><pub-id pub-id-type="pmid">20972870</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rutkowski</surname> <given-names>JM</given-names></name><name><surname>Markhus</surname> <given-names>CE</given-names></name><name><surname>Gyenge</surname> <given-names>CC</given-names></name><name><surname>Alitalo</surname> <given-names>K</given-names></name><name><surname>Wiig</surname> <given-names>H</given-names></name><name><surname>Swartz</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Dermal collagen and lipid deposition correlate with tissue swelling and hydraulic conductivity in murine primary lymphedema</article-title><source>The American Journal of Pathology</source><volume>176</volume><fpage>1122</fpage><lpage>1129</lpage><pub-id pub-id-type="doi">10.2353/ajpath.2010.090733</pub-id><pub-id pub-id-type="pmid">20110415</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Gorham-Stout disease affecting both hands: stabilisation during biphosphonate treatment</article-title><source>HAND</source><volume>6</volume><fpage>85</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1007/s11552-010-9292-6</pub-id><pub-id pub-id-type="pmid">22379445</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spieth</surname> <given-names>ME</given-names></name><name><surname>Greenspan</surname> <given-names>A</given-names></name><name><surname>Forrester</surname> <given-names>DM</given-names></name><name><surname>Ansari</surname> <given-names>AN</given-names></name><name><surname>Kimura</surname> <given-names>RL</given-names></name><name><surname>Gleason-Jordan</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Gorham's disease of the radius: radiographic, scintigraphic, and MRI findings with pathologic correlation. A case report and review of the literature</article-title><source>Skeletal Radiology</source><volume>26</volume><fpage>659</fpage><lpage>663</lpage><pub-id pub-id-type="doi">10.1007/s002560050306</pub-id><pub-id pub-id-type="pmid">9428074</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srinivasan</surname> <given-names>RS</given-names></name><name><surname>Dillard</surname> <given-names>ME</given-names></name><name><surname>Lagutin</surname> <given-names>OV</given-names></name><name><surname>Lin</surname> <given-names>FJ</given-names></name><name><surname>Tsai</surname> <given-names>S</given-names></name><name><surname>Tsai</surname> <given-names>MJ</given-names></name><name><surname>Samokhvalov</surname> <given-names>IM</given-names></name><name><surname>Oliver</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Lineage tracing demonstrates the venous origin of the mammalian lymphatic vasculature</article-title><source>Genes &amp;amp; Development</source><volume>21</volume><fpage>2422</fpage><lpage>2432</lpage><pub-id pub-id-type="doi">10.1101/gad.1588407</pub-id><pub-id pub-id-type="pmid">17908929</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stanczuk</surname> <given-names>L</given-names></name><name><surname>Martinez-Corral</surname> <given-names>I</given-names></name><name><surname>Ulvmar</surname> <given-names>MH</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Laviña</surname> <given-names>B</given-names></name><name><surname>Fruttiger</surname> <given-names>M</given-names></name><name><surname>Adams</surname> <given-names>RH</given-names></name><name><surname>Saur</surname> <given-names>D</given-names></name><name><surname>Betsholtz</surname> <given-names>C</given-names></name><name><surname>Ortega</surname> <given-names>S</given-names></name><name><surname>Alitalo</surname> <given-names>K</given-names></name><name><surname>Graupera</surname> <given-names>M</given-names></name><name><surname>Mäkinen</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>cKit lineage hemogenic endothelium-derived cells contribute to mesenteric lymphatic vessels</article-title><source>Cell Reports</source><fpage>1708</fpage><lpage>1721</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2015.02.026</pub-id><pub-id pub-id-type="pmid">25772358</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veikkola</surname> <given-names>T</given-names></name><name><surname>Jussila</surname> <given-names>L</given-names></name><name><surname>Makinen</surname> <given-names>T</given-names></name><name><surname>Karpanen</surname> <given-names>T</given-names></name><name><surname>Jeltsch</surname> <given-names>M</given-names></name><name><surname>Petrova</surname> <given-names>TV</given-names></name><name><surname>Kubo</surname> <given-names>H</given-names></name><name><surname>Thurston</surname> <given-names>G</given-names></name><name><surname>McDonald</surname> <given-names>DM</given-names></name><name><surname>Achen</surname> <given-names>MG</given-names></name><name><surname>Stacker</surname> <given-names>SA</given-names></name><name><surname>Alitalo</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice</article-title><source>The EMBO Journal</source><volume>20</volume><fpage>1223</fpage><lpage>1231</lpage><pub-id pub-id-type="doi">10.1093/emboj/20.6.1223</pub-id><pub-id pub-id-type="pmid">11250889</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>W</given-names></name><name><surname>Wang</surname> <given-names>H</given-names></name><name><surname>Zhou</surname> <given-names>X</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Sun</surname> <given-names>W</given-names></name><name><surname>Dellinger</surname> <given-names>M</given-names></name><name><surname>Boyce</surname> <given-names>BF</given-names></name><name><surname>Xing</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Lymphatic endothelial cells produce m-csf, causing massive bone loss in mice</article-title><source>Journal of Bone and Mineral Research</source><volume>32</volume><fpage>939</fpage><lpage>950</lpage><pub-id pub-id-type="doi">10.1002/jbmr.3077</pub-id><pub-id pub-id-type="pmid">28052488</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>W</given-names></name><name><surname>Wang</surname> <given-names>H</given-names></name><name><surname>Zhou</surname> <given-names>X</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Sun</surname> <given-names>W</given-names></name><name><surname>Dellinger</surname> <given-names>M</given-names></name><name><surname>Boyce</surname> <given-names>BF</given-names></name><name><surname>Xing</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2017">2017b</year><article-title>Lymphatic endothelial cells produce m-csf, causing massive bone loss in mice</article-title><source>Journal of Bone and Mineral Research</source><volume>32</volume><fpage>939</fpage><lpage>950</lpage><pub-id pub-id-type="doi">10.1002/jbmr.3077</pub-id><pub-id pub-id-type="pmid">28052488</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Witte</surname> <given-names>MH</given-names></name><name><surname>Way</surname> <given-names>DL</given-names></name><name><surname>Witte</surname> <given-names>CL</given-names></name><name><surname>Bernas</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Lymphangiogenesis: mechanisms, significance and clinical implications</article-title><source>Exs</source><volume>79</volume><fpage>65</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1007/978-3-0348-9006-9_5</pub-id><pub-id pub-id-type="pmid">9002221</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname> <given-names>LC</given-names></name><name><surname>Testini</surname> <given-names>C</given-names></name><name><surname>Tvorogov</surname> <given-names>D</given-names></name><name><surname>Anisimov</surname> <given-names>A</given-names></name><name><surname>Vargas</surname> <given-names>SO</given-names></name><name><surname>Baluk</surname> <given-names>P</given-names></name><name><surname>Pytowski</surname> <given-names>B</given-names></name><name><surname>Claesson-Welsh</surname> <given-names>L</given-names></name><name><surname>Alitalo</surname> <given-names>K</given-names></name><name><surname>McDonald</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Pulmonary lymphangiectasia resulting from vascular endothelial growth factor-C overexpression during a critical period</article-title><source>Circulation Research</source><volume>114</volume><fpage>806</fpage><lpage>822</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.114.303119</pub-id><pub-id pub-id-type="pmid">24429550</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yerganyan</surname> <given-names>VV</given-names></name><name><surname>Body</surname> <given-names>JJ</given-names></name><name><surname>De Saint Aubain</surname> <given-names>N</given-names></name><name><surname>Gebhart</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Gorham-Stout disease of the proximal fibula treated with radiotherapy and zoledronic acid</article-title><source>Journal of Bone Oncology</source><volume>4</volume><fpage>42</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.jbo.2015.05.001</pub-id><pub-id pub-id-type="pmid">26579487</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuen</surname> <given-names>D</given-names></name><name><surname>Pytowski</surname> <given-names>B</given-names></name><name><surname>Chen</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Combined blockade of VEGFR-2 and VEGFR-3 inhibits inflammatory lymphangiogenesis in early and middle stages</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>52</volume><fpage>2593</fpage><lpage>2597</lpage><pub-id pub-id-type="doi">10.1167/iovs.10-6408</pub-id><pub-id pub-id-type="pmid">21273538</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zarkada</surname> <given-names>G</given-names></name><name><surname>Heinolainen</surname> <given-names>K</given-names></name><name><surname>Makinen</surname> <given-names>T</given-names></name><name><surname>Kubota</surname> <given-names>Y</given-names></name><name><surname>Alitalo</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>VEGFR3 does not sustain retinal angiogenesis without VEGFR2</article-title><source>PNAS</source><volume>112</volume><fpage>761</fpage><lpage>766</lpage><pub-id pub-id-type="doi">10.1073/pnas.1423278112</pub-id><pub-id pub-id-type="pmid">25561555</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>Q</given-names></name><name><surname>Guo</surname> <given-names>R</given-names></name><name><surname>Lu</surname> <given-names>Y</given-names></name><name><surname>Zhao</surname> <given-names>L</given-names></name><name><surname>Zhou</surname> <given-names>Q</given-names></name><name><surname>Schwarz</surname> <given-names>EM</given-names></name><name><surname>Huang</surname> <given-names>J</given-names></name><name><surname>Chen</surname> <given-names>D</given-names></name><name><surname>Jin</surname> <given-names>ZG</given-names></name><name><surname>Boyce</surname> <given-names>BF</given-names></name><name><surname>Xing</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>VEGF-C, a lymphatic growth factor, is a RANKL target gene in osteoclasts that enhances osteoclastic bone resorption through an autocrine mechanism</article-title><source>Journal of Biological Chemistry</source><volume>283</volume><fpage>13491</fpage><lpage>13499</lpage><pub-id pub-id-type="doi">10.1074/jbc.M708055200</pub-id><pub-id pub-id-type="pmid">18359770</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname> <given-names>W</given-names></name><name><surname>Aspelund</surname> <given-names>A</given-names></name><name><surname>Alitalo</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Lymphangiogenic factors, mechanisms, and applications</article-title><source>Journal of Clinical Investigation</source><volume>124</volume><fpage>878</fpage><lpage>887</lpage><pub-id pub-id-type="doi">10.1172/JCI71603</pub-id><pub-id pub-id-type="pmid">24590272</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>Z</given-names></name><name><surname>Feng</surname> <given-names>JQ</given-names></name><name><surname>Dusevich</surname> <given-names>VM</given-names></name><name><surname>Sinha</surname> <given-names>K</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Darnay</surname> <given-names>BG</given-names></name><name><surname>de Crombrugghe</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Multiple functions of Osterix are required for bone growth and homeostasis in postnatal mice</article-title><source>PNAS</source><volume>107</volume><fpage>12919</fpage><lpage>12924</lpage><pub-id pub-id-type="doi">10.1073/pnas.0912855107</pub-id><pub-id pub-id-type="pmid">20615976</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.34323.018</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Gerhardt</surname><given-names>Holger</given-names></name><role>Reviewing Editor</role><aff id="aff9"><institution>Max Delbrück Centre for Molecular Medicine</institution><country>Germany</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>Thank you for submitting your article &quot;VEGF-C promotes the development of lymphatics in bone and bone loss&quot; for consideration by <italic>eLife</italic>. Your article has been favorably evaluated by Didier Stainier (Senior Editor) and four reviewers, one of whom, Holger Gerhardt (Reviewer #1), is a member of our Board of Reviewing Editors. The following individuals involved in review of your submission have also agreed to reveal their identity: Joyce Bischoff (Reviewer #2); Baptiste Coxam (Reviewer #4).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>Summary:</p><p>The presented study shows that transgenic overexpression of VEGF-C in murine bone induces abnormal formation of lymphatic vessels in the bone, where they are not normally present. This is associated with increased number and activity of osteoclasts and bone loss. Intriguingly, the phenotype can be reversed after inhibition of VEGF-C expression. The <italic>OsxtTA;TetO-Vegfc</italic> mouse model generated in this study thus recapitulates features of, and provides the first animal model for a human disease called Gorham-Stout disease (GSD). The authors provide a comprehensive and convincing characterization of the phenotype, and the study raises many interesting questions, some of which are discussed by the authors.</p><p>Essential revisions:</p><p>The reviewers all find the work of substantial interest and great value for the GSD community as a model that may allow for deeper mechanistic understanding of the pathogenesis and therefore possible treatment of this disease. However, they all expressed concerns that in its present form, the manuscript is not strong enough in two points, a) the validity of the model for GSD, (i.e. is VEGF-C the driver of GSD in patients and are the lymphatics directly the cause of bone degradation, or is there a direct effect of VEGF-C on osteoclasts involved?) and b) the utility of the model to understand pathogenesis for example by investigating the origin of the ectopic lymphatic vessels. Following discussions, the reviewers agreed that the latter point may represent a future direction beyond the scope of a revision and only represents added value if the former point, the validity of the model, is sufficiently substantiated. They therefore request the following essential revisions:</p><p>1) Further validation as GSD model ideally on patient material if possible (including VEGF-C and osteoclast staining). The reviewers recognise however that obtaining patient material of good quality may be challenging.</p><p>2) Deeper investigation into the functional consequences of the performed VEGFR2 and 3 inhibition including assessment of osteoclasts, TRAP staining, and bone porosity as well as bone strength measurement. Given that reduction of osteoclasts using Zoledronic acid treatment (Figure 4) reduces bone destruction without affecting lymphatic vessels, it is critical to understand whether a treatment that primarily reduces lymphatics will affect osteoclasts and bone destruction. This should help to untangle possible direct from indirect effects of VEGF-C on bone.</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.34323.019</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><p>Essential revisions:</p><disp-quote content-type="editor-comment"><p>The reviewers all find the work of substantial interest and great value for the GSD community as a model that may allow for deeper mechanistic understanding of the pathogenesis and therefore possible treatment of this disease. However, they all expressed concerns that in its present form, the manuscript is not strong enough in two points, a) the validity of the model for GSD, (i.e. is VEGF-C the driver of GSD in patients and are the lymphatics directly the cause of bone degradation, or is there a direct effect of VEGF-C on osteoclasts involved?) and b) the utility of the model to understand pathogenesis for example by investigating the origin of the ectopic lymphatic vessels. Following discussions, the reviewers agreed that the latter point may represent a future direction beyond the scope of a revision and only represents added value if the former point, the validity of the model, is sufficiently substantiated. They therefore request the following essential revisions:</p><p>1) Further validation as GSD model ideally on patient material if possible (including VEGF-C and osteoclast staining). The reviewers recognise however that obtaining patient material of good quality may be challenging.</p></disp-quote><p>GSD patient samples are very rare and they are frequently decalcified with acid so a pathologist can analyze them. This makes it very difficult to perform molecular studies and specific stains (e.g. TRAP staining) with GSD patient samples. We have tried to obtain high-quality patient material for several years. Unfortunately, we do not have samples that would allow us to determine whether VEGF-C is locally elevated in patients with GSD. Although we haven’t been able to measure VEGF-C in patients with GSD, we believe that our mice will be of great value to the GSD research community. Our transgenic mice can be used to answer fundamental questions regarding the biology of bone lymphatics. We believe that this knowledge will significantly advance our understanding of processes that are relevant to the pathophysiology of GSD.</p><disp-quote content-type="editor-comment"><p>2) Deeper investigation into the functional consequences of the performed VEGFR2 and 3 inhibition including assessment of osteoclasts, TRAP staining, and bone porosity as well as bone strength measurement. Given that reduction of osteoclasts using Zoledronic acid treatment (Figure 4) reduces bone destruction without affecting lymphatic vessels, it is critical to understand whether a treatment that primarily reduces lymphatics will affect osteoclasts and bone destruction. This should help to untangle possible direct from indirect effects of VEGF-C on bone.</p></disp-quote><p>To address the comment, we measured osteoclast number and bone porosity in femurs from vehicle and mF4-31C1-treated mice. We focused our analysis on mF4-31C1-treated mice because these mice do not develop bone lymphatics. Importantly, we found that mF4-31C1 inhibited osteoclastogenesis and bone loss in <italic>Osx-tTA;TetO-Vegfc</italic> mice. We have added these new findings to the manuscript.</p><p>Results: “To determine whether inhibition of lymphangiogenesis could prevent osteoclastogenesis and bone loss in <italic>Osx-tTA;TetO-Vegfc</italic> mice, we analyzed femurs from vehicle and mF4-31C1-treated mice. […] These data show that inhibition of lymphangiogenesis can prevent osteoclastogenesis and bone loss in <italic>Osx-tTA;TetO-Vegfc</italic> mice.”</p><p>Figure Legend 5: “Figure 5. mF4-31C1 inhibits osteoclast formation and bone loss in <italic>Osx-tTA;TetO-Vegfc</italic> mice. […] (G) Graph showing cortical bone porosity of femurs for vehicle-treated (0.07244 ± 0.02468, n=5) and mF4-31C1-treated (0.006375 ± 0.007087, n=4) mice. (** <italic>P</italic> &lt; 0.01, unpaired student’s T-test)”</p><p>We measured bone strength in <italic>Osx-tTA</italic> and <italic>Osx-tTA;TetO-Vegfc</italic> mice by performing a three-point bending assay. This assay was performed in the fall of 2017 and was the last experiment we performed before submitting the manuscript for review. Importantly, the three-point bending assay is performed with freshly isolated unfixed samples. We did not perform the three-point bending assay with samples collected from mice that received vehicle, DC101, or mF4-31C1 because that animal experiment was performed in 2015; before we knew there were differences in bone strength between <italic>Osx-tTA</italic> and <italic>Osx-tTA;TetO-Vegfc</italic> mice. Unfortunately, we do not have unfixed samples from vehicle, DC101, or mF4-31C1-treated mice for the three-point bending assay. However, we have been able to show that mF4-31C1-treated mice have less porous bones than vehicle-treated mice (Figure 5). Based on this observation, we predict that mF4-31C1-treated mice would have stronger bones than vehicle-treated mice.</p></body></sub-article></article>